

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 November 2001 (01.11.2001)

PCT

(10) International Publication Number
WO 01/81325 A2

(51) International Patent Classification⁷: C07D 273/00

(21) International Application Number: PCT/US01/12530

(22) International Filing Date: 17 April 2001 (17.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/198,204 19 April 2000 (19.04.2000) US

(71) Applicant: SCHERING CORPORATION [US/US];
2000 Galloping Hill Road, Kenilworth, NJ 07033-0530
(US).

(72) Inventors: VENKATRAMAN, Srikanth; 35 Roanoke
Street, Woodbridge, NJ 07095 (US). CHEN, Kevin, X.;
44 Gill Lane, Apt. 1D, Iselin, NJ 08830 (US). ARASAP-
PAN, Ashok; 18 Larsen Court, Bridgewater, NJ 08807
(US). NJORGE, F., George; 11 Softwood Way, War-
ren, NJ 07059 (US). GIRIJAVALLABHAN, Viyyoor,
M.; 10 Maplewood Drive, Parsippany, NJ 07054 (US).
CHAN, Tin-Yau; 26 Barlow Road, Edison, NJ 08817
(US). MCKITTRICK, Brian, A.; 67 Laurel Avenue,

Bloomfield, NJ 07003 (US). PRONGAY, Andrew, J.;
104 Willow Grove Road, Stewartville, NJ 08886 (US).
MADISON, Vincent, S.; 12 Ronarm Drive, Mountain
Lakes, NJ 07046 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID,
IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA,
MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN,
YU, ZA.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING ALKYL AND
ARYL ALANINE P2 MOIETIES

(57) Abstract: The present invention discloses novel macrocyclic compounds which have HCV protease inhibitory activity as well
as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising
such macrocycles as well as methods of using them to treat disorders associated with the HCV protease.

WO 01/81325 A2

**Macrocyclic NS-3 Serine Protease Inhibitors of Hepatitis C Virus comprising
Alkyl and Aryl Alanine P2 Moieties**

Field of invention

The present invention relates to novel hepatitis C virus ("HCV") protease inhibitors, pharmaceutical compositions containing one or more such inhibitors, methods of preparing such inhibitors and methods of using such inhibitors to treat hepatitis C and related disorders. This invention specifically discloses novel macrocyclic compounds as inhibitors of the HCV NS3/NS4a serine protease. The disclosure herein is related to that in pending patent application, Serial No. _____, filed April 5, 2000.

Background of the invention

Hepatitis C virus (HCV) is a (+)-sense single-stranded RNA virus that has been implicated as the major causative agent in non-A, non-B hepatitis (NANBH), particularly in blood-associated NANBH (BB-NANBH)(see, International Patent Application Publication No. WO 89/04669 and European Patent Application Publication No. EP 381 216). NANBH is to be distinguished from other types of viral-induced liver disease, such as hepatitis A virus (HAV), hepatitis B virus (HBV), delta hepatitis virus (HDV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV), as well as from other forms of liver disease such as alcoholism and primary biliar cirrhosis.

Recently, an HCV protease necessary for polypeptide processing and viral replication has been identified, cloned and expressed; (see, e.g., U.S. Patent No. 5,712,145). This approximately 3000 amino acid polyprotein contains, from the amino terminus to the carboxy terminus, a nucleocapsid protein (C), envelope proteins (E1 and E2) and several non-structural proteins (NS1, 2, 3, 4a, 5a and 5b). NS3 is an approximately 68 kda protein, encoded by approximately 1893 nucleotides of the HCV genome, and has two distinct domains: (a) a serine protease domain consisting of approximately 200 of the N-terminal amino acids; and (b) an RNA-dependent ATPase domain at the C-terminus of the protein. The

NS3 protease is considered a member of the chymotrypsin family because of similarities in protein sequence, overall three-dimensional structure and mechanism of catalysis. Other chymotrypsin-like enzymes are elastase, factor Xa, thrombin, trypsin, plasmin, urokinase, tPA and PSA. The HCV NS3 serine protease is responsible for proteolysis of the polypeptide (polyprotein) at the NS3/NS4a, NS4a/NS4b, NS4b/NS5a and NS5a/NS5b junctions and is thus responsible for generating four viral proteins during viral replication. This has made the HCV NS3 serine protease an attractive target for antiviral chemotherapy.

It has been determined that the NS4a protein, an approximately 6 kda polypeptide, is a co-factor for the serine protease activity of NS3. Autocleavage of the NS3/NS4a junction by the NS3/NS4a serine protease occurs intramolecularly (*i.e.*, *cis*) while the other cleavage sites are processed intermolecularly (*i.e.*, *trans*).

Analysis of the natural cleavage sites for HCV protease revealed the presence of cysteine at P1 and serine at P1' and that these residues are strictly conserved in the NS4a/NS4b, NS4b/NS5a and NS5a/NS5b junctions. The NS3/NS4a junction contains a threonine at P1 and a serine at P1'. The Cys→Thr substitution at NS3/NS4a is postulated to account for the requirement of *cis* rather than *trans* processing at this junction. See, *e.g.*, Pizzi *et al.* (1994) Proc. Natl. Acad. Sci (USA) 91:888-892, Failla *et al.* (1996) Folding & Design 1:35-42. The NS3/NS4a cleavage site is also more tolerant of mutagenesis than the other sites. See, *e.g.*, Kollykhalov *et al.* (1994) J. Virol. 68:7525-7533. It has also been found that acidic residues in the region upstream of the cleavage site are required for efficient cleavage. See, *e.g.*, Komoda *et al.* (1994) J. Virol. 68:7351-7357.


Inhibitors of HCV protease that have been reported include antioxidants (see, International Patent Application Publication No. WO 98/14181), certain peptides and peptide analogs (see, International Patent Application Publication No. WO 98/17679, Landro *et al.* (1997) Biochem. 36:9340-9348, Ingallinella *et al.* (1998) Biochem. 37:8906-8914, Llinàs-Brunet *et al.* (1998) Bioorg. Med. Chem. Lett. 8:1713-1718), inhibitors based on the 70-amino acid polypeptide eglin c (Martin *et al.* (1998) Biochem. 37:11459-11468, inhibitors affinity selected from

human pancreatic secretory trypsin inhibitor (hPSTI-C3) and minibody repertoires (MBip) (Dimasi *et al.* (1997) *J. Virol.* 71:7461-7469), cV_HE2 (a "camelized" variable domain antibody fragment) (Martin *et al.* (1997) *Protein Eng.* 10:607-614), and α 1-antichymotrypsin (ACT) (Elzouki *et al.* (1997) *J. Hepat.* 27:42-28). A
5 ribozyme designed to selectively destroy hepatitis C virus RNA has recently been disclosed (see, *BioWorld Today* 9(217): 4 (November 10, 1998)).


Reference is also made to the PCT Publications, No. WO 98/17679, published April 30, 1998 (Vertex Pharmaceuticals Incorporated); WO 98/22496, published May 28, 1998 (F. Hoffmann-La Roche AG); and WO 99/07734,
10 published February 18, 1999 (Boehringer Ingelheim Canada Ltd.).

HCV has been implicated in cirrhosis of the liver and in induction of hepatocellular carcinoma. The prognosis for patients suffering from HCV infection is currently poor. HCV infection is more difficult to treat than other forms of hepatitis due to the lack of immunity or remission associated with HCV infection.
15 Current data indicates a less than 50% survival rate at four years post cirrhosis diagnosis. Patients diagnosed with localized resectable hepatocellular carcinoma have a five-year survival rate of 10-30%, whereas those with localized unresectable hepatocellular carcinoma have a five-year survival rate of less than 1%.


20 Reference is made to A. Marchetti *et al.*, *Synlett*, S1, 1000-1002 (1999) describing the synthesis of bicyclic analogs of an inhibitor of HCV NS3 protease. A compound disclosed therein has the formula:




25 Reference is also made to WO 00/09558 (Assignee: Boehringer Ingelheim Limited; Published February 24, 2000) which discloses peptide derivatives of the formula:




where the various elements are defined therein. An illustrative compound of that series is:



Reference is also made to WO 00/09543 (Assignee: Boehringer Ingelheim Limited; Published February 24, 2000) which discloses peptide derivatives of the formula:



- 5 where the various elements are defined therein. An illustrative compound of that series is:



Current therapies for hepatitis C include interferon- α (INF α) and combination therapy with ribavirin and interferon. See, e.g., Beremguer et al. (1998) Proc. Assoc. Am. Physicians 110(2):98-112. These therapies suffer from a low sustained response rate and frequent side effects. See, e.g., Hoofnagle et al. (1997) N. Engl. J. Med. 336:347. Currently, no vaccine is available for HCV infection.

Pending patent application, Serial Number, _____, filed April 5, 2000, discloses certain macrocyclic compounds as inhibitors of the HCV protease as well as pharmaceutical compositions containing said compounds.

There is a need for new treatments and therapies for HCV infection. It is, therefore, an object of this invention to provide compounds useful in the treatment or prevention or amelioration of one or more symptoms of hepatitis C.

It is a further object herein to provide methods of treatment or prevention or amelioration of one or more symptoms of hepatitis C.


A still further object of the present invention is to provide methods for modulating the activity of serine proteases, particularly the HCV NS3/NS4a serine protease, using the compounds provided herein.

Another object herein is to provide methods of modulating the processing of the HCV polypeptide using the compounds provided herein.

Summary of the invention

In its many embodiments, the present invention provides a novel class of macrocyclic inhibitors of the HCV protease, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration of one or more of the symptoms of hepatitis C. Also provided are methods of modulating the interaction of an HCV polypeptide with HCV protease. Among the compounds provided herein, compounds that inhibit HCV NS3/NS4a serine protease activity are preferred. The presently disclosed compounds generally contain about four or more amino acid residues and less than about twelve amino acid residues.

In its principal embodiment, the present invention provides a macrocyclic compound of Formula I:



Formula I

wherein:

E, X and Y may be independently present or absent, and if present are independently selected from the moieties: alkyl, aryl, alkyl-aryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl, alkyl ether, alkyl-aryl ether, aryl ether, alkyl amino, aryl amino, alkyl-aryl amino, alkyl sulfide, alkyl-aryl sulfide, aryl sulfide, alkyl sulfone, alkyl-aryl sulfone, aryl sulfone, alkyl-alkyl sulfoxide, alkyl-aryl sulfoxide, alkyl amide, alkyl-aryl amide, aryl amide, alkyl sulfonamide, alkyl-aryl sulfonamide, aryl sulfonamide, alkyl urea, alkyl-aryl urea, aryl urea, alkyl carbamate, alkyl-aryl carbamate, aryl carbamate, alkyl -hydrazide, alkyl-aryl hydrazide, alkyl hydroxamide, alkyl-aryl hydroxamide, alkyl sulfonyl, aryl sulfonyl, heteroalkyl sulfonyl, heteroaryl sulfonyl, alkyl carbonyl, aryl carbonyl, heteroalkyl carbonyl, heteroaryl carbonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl or a combination thereof, with the proviso that E, X and Y may optionally be additionally substituted with moieties selected from the group consisting of aromatic, alkyl, alkyl-aryl, heteroalkyl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl, alkyl ether, alkyl-aryl ether, alkyl sulfide, alkyl-aryl sulfide, alkyl sulfone, alkyl-aryl sulfone, alkyl amide, alkyl-aryl amide, alkyl sulfonamide, , alkyl amines, alkyl-aryl amines, alkyl-aryl sulfonamide, alkyl urea, alkyl-aryl urea,

alkyl carbamate, alkyl-aryl carbamate, halogen, hydroxyl amino, alkyl carbazate, aryl carbazate;

$R^1 = COR^5$ or $B(OR)_2$, wherein $R^5 = H, OH, OR^8, NR^9R^{10}, CF_3, C_2F_5, C_3F_7, CF_2R^6, R^6, COR^7$ wherein $R^7 = H, OH, OR^8, CHR^9R^{10},$ or NR^9R^{10} , wherein $R^6,$
 5 R^8, R^9 and R^{10} are independently selected from the group consisting of H, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, cycloalkyl, arylalkyl, heteroarylalkyl, $CH(R^1)COOR^{11}, CH(R^1)CONR^{12}R^{13},$
 $CH(R^1)CONHCH(R^2)COO R^{11}, CH(R^1)CONHCH(R^2)CONR^{12}R^{13},$
 $CH(R^1)CONHCH(R^2)R', CH(R^1)CONHCH(R^2)CONHCH(R^3)COO R^{11},$
 10 $CH(R^1)CONHCH(R^2)CONHCH(R^3)CONR^{12}R^{13},$
 $CH(R^1)CONHCH(R^2)CONHCH(R^3)CONHCH(R^4)COO R^{11},$
 $CH(R^1)CONHCH(R^2)CONHCH(R^3)CONHCH(R^4)CONR^{12}R^{13},$
 $CH(R^1)CONHCH(R^2)CONHCH(R^3)CONHCH(R^4)CONHCH(R^5)COO R^{11}, CH(R^1)$
 $)CONHCH(R^2)CONHCH(R^3)CONHCH(R^4)CONHCH(R^5)CONR^{12}R^{13},$ wherein
 15 $R^1, R^2, R^3, R^4, R^5, R^{11}, R^{12}, R^{13},$ and R' are independently selected from a group consisting of H, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, alkyl-aryl, alkyl-heteroaryl, aryl-alkyl and heteroaralkyl;

Z is selected from O, N, or CH;

W may be present or absent, and if W is present, W is selected from C=O,
 20 C=S, SO₂ or C=NR;

Q is $(NR)_p, O, S, CH_2, CHR, CRR'$ or a double bond towards V;

A is O, CH₂, $(CHR)_p, (CHR-CHR')_p, (CRR')_p, NR, S, SO_2, C=O$ or a bond;

G is $(CH_2)_p, (CHR)_p, (CRR')_p, NR, O, S, SO_2, S(O)_2NH, C=O,$ or a double
 25 bond towards E or V;

V is CH, CR or N;

p is a number from 0 to 6; and

R, R', R^2, R^3 and R^4 are independently selected from the group consisting of H; C1-C10 alkyl; C2-C10 alkenyl; C3-C8 cycloalkyl; C3-C8 heterocycloalkyl,
 30 aryl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro; heteroaryl; alkyl-aryl; alkyl-

heteroaryl; (cycloalkyl)alkyl and (heterocycloalkyl)alkyl, wherein said cycloalkyl is made of three to eight carbon atoms, and zero to six oxygen, nitrogen, sulfur, or phosphorus atoms, and said alkyl is of one to six carbon atoms;

with said alkyl, heteroalkyl, alkenyl, heteroalkenyl, aryl, heteroaryl, cycloalkyl and
5 heterocycloalkyl moieties may be optionally substituted, with said term

“substituted” referring to optional and suitable substitution with one or more moieties selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, heterocyclic, halogen, hydroxy, thio, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano,
10 nitro, sulfonamide, sulfoxide, sulfone, sulfonyl urea, hydrazide, and hydroxamate and thiourea.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. Thus, for example, the term alkyl (including the alkyl
15 portions of alkoxy) refers to a monovalent group derived from a straight or branched chain saturated hydrocarbon by the removal of a single atom having from 1 to 8 carbon atoms, preferably from 1 to 6;

aryl – represents a carbocyclic group having from 6 to 14 carbon atoms and having at least one benzenoid ring, with all available substitutable aromatic
20 carbon atoms of the carbocyclic group being intended as possible points of attachment. Preferred aryl groups include phenyl, 1-naphthyl, 2-naphthyl and indanyl, and especially phenyl and substituted phenyl;

aralkyl – represents a moiety containing an aryl group linked via a lower alkyl;

25 alkylaryl – represents a moiety containing a lower alkyl linked via an aryl group;

cycloalkyl – represents a saturated carbocyclic ring having from 3 to 8 carbon atoms, preferably 5 or 6, optionally substituted;

heterocyclic – represents, in addition to the heteroaryl groups defined
30 below, saturated and unsaturated cyclic organic groups having at least one O, S and/or N atom interrupting a carbocyclic ring structure that consists of one or more

rings, wherein each ring is 5-, 6- or 7-membered and may or may not have double bonds that lack delocalized pi electrons, which ring structure has from 2 to 8, preferably from 3 to 6 carbon atoms, e.g., 2- or 3-piperidinyl, 2- or 3-piperazinyl, 2- or 3-morpholinyl, or 2- or 3-thiomorpholinyl;

5 halogen – represents fluorine, chlorine, bromine and iodine;

 heteroaryl – represents a cyclic organic group having at least one O, S and/or N atom interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character, with the aromatic heterocyclic group having from 2 to 14, preferably 4 or 5 carbon atoms,
10 e.g., 2-, 3- or 4-pyridyl, 2- or 3-furyl, 2- or 3-thienyl, 2-, 4- or 5-thiazolyl, 2- or 4-imidazolyl, 2-, 4- or 5-pyrimidinyl, 2-pyrazinyl, or 3- or 4-pyridazinyl, etc. Preferred heteroaryl groups are 2-, 3- and 4-pyridyl; Such heteroaryl groups may also be optionally substituted.

 Also included in the invention are tautomers, rotamers, enantiomers and
15 other optical isomers of compounds of Formula I, as well as pharmaceutically acceptable salts and solvates thereof.

 A further feature of the invention is pharmaceutical compositions containing as active ingredient a compound of Formula I (or its salt, solvate or isomers) together with a pharmaceutically acceptable carrier or excipient.


20 The invention also provides methods for preparing compounds of Formula I, as well as methods for treating diseases such as, for example, HCV and related disorders. The methods for treating comprise administering to a patient suffering from said disease or diseases a therapeutically effective amount of a compound of Formula I, or pharmaceutical compositions comprising a compound of Formula I.

25 Also disclosed is the use of a compound of Formula I for the manufacture of a medicament for treating HCV and related disorders.

Detailed description of preferred embodiments


 In one embodiment, the present invention discloses compounds of Formula
30 I as inhibitors of HCV protease, especially the HCV NS3/NS4a serine protease:

11




where the various moieties are defined above. Some of the preferred
embodiments include, but are not limited to, the following definitions of the various
functionalities in the above-noted general formula I; other desired definitions for
the same and additional functionalities may be found in the structures and claims
of this application which are also within the contemplation of the present invention.
Among the preferred embodiments, R² in formula I may be selected from the
following moieties:

12




E may be a substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl or substituted or unsubstituted cycloalkyl, with preferred representations for E being:



5

Preferred embodiments for R^3 include the moieties:

13




wherein $R^{30} = \text{H}, \text{CH}_3$ or other alkyl groups;

$R^{31} = \text{OH}, \text{O-alkyl}, \text{NH}_2, \text{N-alkyl}$; and

- 5 R^{32} and R^{33} may be the same or different and are selected independently from H, F, Cl, Br and CH_3 .

Preferred embodiments for the moiety X-Y are the following structures:


14




Several additional and further refinements of the above-noted various definitions for the compounds represented by Formula I are noted in the **Claims** section of this application. They are also represented by the various compounds listed in the specification and claims. Such refinements, definitions and limitations are to be considered as representing the entire invention of this application.

Representative compounds of the invention which exhibit excellent HCV protease inhibitory activity are listed below:


15




1



2




3




4


16




5



6




7




8


17




9



10




11




12


18




13



14




15




16


19




17



18




19




20


20




21



22




23




24


21




25



26




27




28


22




29



30




31




32


23




33



34




35




36


24




37



38




39




40


25




41



42







43




44


26




27




49





50



51



52



The activity of some of the compounds are presented in **Table 1** as ranges of K_i values in nanomolar (nM). The Example numbers in **Table 1** refer to the numbers
5 for the various structures in the EXAMPLES section found in the later parts of this application.

Table 1: HCV protease continuous assay results

Example number	K_i^* nM
1	B
2	A
3	B
4	B
5	B
6	A
7	B
8	A

9	B
10	B
11	B
12	A
13	B
14	B
15	B
16	A
17	B
18	A
19	B
20	A
21	B
22	A
23	B
24	B
25	B
26	B
27	B
28	B
29	B
30	A
31	B
32	B
33	B
34	B
35	B
36	B
37	B
38	B

39	A
40	B
41	A
42	B
43	A
44	A
45	B
46	B
47	B
48	B
49	B
50	B
51	B
52	A
53	A
54	B

HCV continuous assay K_i^* range:

Category A= 0.001-1.0 μ M, Category B= 1.1-100 μ M

Some methods of synthesizing the various types of the inventive
5 compounds are described later in this section, and also schematically described,
followed by the illustrative Examples.

Depending upon the structure, the compounds of the invention may form
pharmaceutically acceptable salts with organic or inorganic acids, or organic or
inorganic bases. Examples of suitable acids for such salt formation are
10 hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic,
fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and
carboxylic acids well known to those skilled in the art. For formation of salts with
bases, suitable bases are, for example, NaOH, KOH, NH_4OH ,
tetraalkylammonium hydroxide, and the like.

In another embodiment, this invention provides pharmaceutical compositions comprising the above-described inventive macrocycles as an active ingredient. The pharmaceutical compositions generally additionally comprise a pharmaceutically acceptable carrier diluent, excipient or carrier (collectively referred to herein as carrier materials). Because of their HCV inhibitory activity, such pharmaceutical compositions possess utility in treating hepatitis C and related disorders.

In yet another embodiment, the present invention discloses methods for preparing pharmaceutical compositions comprising the inventive macrocycle compounds as an active ingredient. In the pharmaceutical compositions and methods of the present invention, the active ingredients will typically be administered in admixture with suitable carrier materials suitably selected with respect to the intended form of administration, i.e. oral tablets, capsules (either solid-filled, semi-solid filled or liquid filled), powders for constitution, oral gels, elixirs, dispersible granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices. For example, for oral administration in the form of tablets or capsules, the active drug component may be combined with any oral non-toxic pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and the like. Moreover, when desired or needed, suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated in the mixture. Powders and tablets may be comprised of from about 5 to about 95 percent inventive composition. Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. Among the lubricants there may be mentioned for use in these dosage forms, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include starch, methylcellulose, guar gum and the like.

Sweetening and flavoring agents and preservatives may also be included where appropriate. Some of the terms noted above, namely disintegrants, diluents, lubricants, binders and the like, are discussed in more detail below.

Additionally, the compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects, i.e. HCV inhibitory activity and the like. Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injections or addition of sweeteners and pacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.

For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

The compounds of the invention may also be deliverable transdermally. The transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

Preferably the compound is administered orally.

Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.

5 The quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 1.0 milligram to about 1,000 milligrams, preferably from about 1.0 to about 950 milligrams, more preferably from about 1.0 to about 500 milligrams, and typically from about 1 to about 250 milligrams, according to the particular application. The actual dosage
10 employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art.

 Generally, the human oral dosage form containing the active ingredients can be administered 1 or 2 times per day. The amount and frequency of the
15 administration will be regulated according to the judgment of the attending clinician. A generally recommended daily dosage regimen for oral administration may range from about 1.0 milligram to about 1,000 milligrams per day, in single or divided doses.

 Some useful terms are described below:

20 Capsule - refers to a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredients. Hard shell capsules are typically made of blends of relatively high gel strength bone and pork skin gelatins. The capsule itself may contain small amounts of dyes, opaquing agents,
25 plasticizers and preservatives.

 Tablet- refers to a compressed or molded solid dosage form containing the active ingredients with suitable diluents. The tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or by compaction.

30 Oral gel- refers to the active ingredients dispersed or solubilized in a hydrophillic semi-solid matrix.

Powder for constitution refers to powder blends containing the active ingredients and suitable diluents which can be suspended in water or juices.

Diluent - refers to substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potato; and celluloses such as microcrystalline cellulose. The amount of diluent in the composition can range from about 10 to about 90% by weight of the total composition, preferably from about 25 to about 75%, more preferably from about 30 to about 60% by weight, even more preferably from about 12 to about 60%.

Disintegrant - refers to materials added to the composition to help it break apart (disintegrate) and release the medicaments. Suitable disintegrants include starches; "cold water soluble" modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose; microcrystalline celluloses and cross-linked microcrystalline celluloses such as sodium croscarmellose; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures. The amount of disintegrant in the composition can range from about 2 to about 15% by weight of the composition, more preferably from about 4 to about 10% by weight.

Binder - refers to substances that bind or "glue" powders together and make them cohesive by forming granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose; starches derived from wheat, corn rice and potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate; cellulosic materials such as methylcellulose and sodium carboxymethylcellulose and hydroxypropylmethylcellulose; polyvinylpyrrolidone; and inorganics such as magnesium aluminum silicate. The amount of binder in the composition can range from about 2 to about 20% by

weight of the composition, more preferably from about 3 to about 10% by weight, even more preferably from about 3 to about 6% by weight.

Lubricant - refers to a substance added to the dosage form to enable the tablet, granules, etc. after it has been compressed, to release from the mold or die by reducing friction or wear. Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; high melting point waxes; and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and d,l-leucine. Lubricants are usually added at the very last step before compression, since they must be present on the surfaces of the granules and in between them and the parts of the tablet press. The amount of lubricant in the composition can range from about 0.2 to about 5% by weight of the composition, preferably from about 0.5 to about 2%, more preferably from about 0.3 to about 1.5% by weight.

Glident - material that prevents caking and improve the flow characteristics of granulations, so that flow is smooth and uniform. Suitable glidents include silicon dioxide and talc. The amount of glident in the composition can range from about 0.1% to about 5% by weight of the total composition, preferably from about 0.5 to about 2% by weight.

Coloring agents - excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes and food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide. The amount of the coloring agent can vary from about 0.1 to about 5% by weight of the composition, preferably from about 0.1 to about 1%.

Bioavailability - refers to the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control.

Conventional methods for preparing tablets are known. Such methods include dry methods such as direct compression and compression of granulation produced by compaction, or wet methods or other special procedures.

Conventional methods for making other forms for administration such as, for example, capsules, suppositories and the like are also well known.

Another embodiment of the invention discloses the use of the pharmaceutical compositions disclosed above for treatment of diseases such as, for example, hepatitis C the like. The method comprises administering a therapeutically effective amount of the inventive pharmaceutical composition to a patient having such a disease or diseases and in need of such a treatment.

As stated earlier, the invention includes tautomers, enantiomers and other stereoisomers of the compounds also. Thus, as one skilled in the art knows, some of the inventive compounds may exist in isomeric forms. Such variations are contemplated to be within the scope of the invention.

Another embodiment of the invention discloses a method of making the macrocyclic compounds disclosed herein. The compounds may be prepared by several techniques known in the art. Representative illustrative procedures are outlined in the following reaction schemes. It is to be understood that while the following illustrative schemes describe the preparation of macrocycles predominately derived from *meta*-tyrosine or lysine at the P2 position. Suitable substitution of any of both the natural and unnatural amino acids will result in the formation of the desired macrocycles based on such substitution.

Abbreviations which are used in the descriptions of the schemes, preparations and the examples that follow are:

THF: Tetrahydrofuran

DMF: *N,N*-Dimethylformamide

EtOAc: Ethyl acetate

AcOH: Acetic acid

HOObt: 3-Hydroxy-1,2,3-benzotriazin-4(3*H*)-one

EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

NMM: *N*-Methylmorpholine

ADDP: 1,1'-(Azodicarbonyl)dipiperidine

DEAD: Diethylazodicarboxylate

MeOH: Methanol

EtOH: Ethanol

Et₂O: Diethyl ether

Bn: Benzyl

Boc: tert-Butyloxycarbonyl

Cbz: Benzyloxycarbonyl

Cp: Cyclopentylidienyl

5 Ts: p-toluenesulfonyl

Me: Methyl

HATU: O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate

Chg: Cyclohexylglycine

10 Tyr: Tyrosine

G: Glycerol

TG: Thioglycerol

alloc: allyloxycarbonyl

Fmoc: 9-Fluorenyl methyloxycarbonyl

15 Dde: N-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl

tBu: *tert*-butyl

equiv: equivalent

rel. int.: relative intensity

aq: aqueous

20 rt: room temperature

satd: saturated

Hex: hexane(s)

NBA: Nitrobenzoic acid

PyBrOP: Tris(pyrrolidino)bromophosphonium hexafluorophosphate

25 DMSO: Dimethyl sulfoxide

TFA: Trifluoroacetic acid

HOBt: Hydroxybenzotriazole

Hünigs base: Diisopropylethyl amine

BOP: Benzo[1,2,3-c]oxazolidine-1-yl-tris(dimethylamino)phosphonium hexafluorophosphate

30 LDA: Lithium diisopropyl amide

Ph₃P: Triphenyl phosphine

LAH: Lithium Aluminum Hydride

DMAP: 4-Dimethyl aminopyridine

DCC: Dicyclohexylcarbodiimide

MCPBA: meta-Chloroperbenzoic acid

5 BINAP: 2,2'-Bis(diphenylphosphino)-1,1'-binaphtol


MeCN: acetonitrile

Pr: Propyl


Ac: Acetyl

Ph: Phenyl


10 **General Schemes for Synthesis of Inventive Compounds:** In the following
Schemes, n is a number from 1 to 6.

Scheme 1:


- 5 The synthesis of compounds of type **1e** wherein R¹, R², R³, R' are defined above, R⁴ being amide, carbamate, or hydrogen, R being alkyl, aryl or arylalkyl, began with the coupling of **1a** with the dipeptide **1b** using NMM, HOBT, and EDCI to obtain the intermediate **1c**. The intermediate **1c** was treated with Cs₂CO₃ in DMF followed by photolysis to obtain compound **1d**. The macrocyclic ester **1d** was hydrolyzed and coupled with a suitable amine intermediate to generate compounds of type **1e**.
- 10

Scheme 2:


5 The preparation of the compound of formula **2e**, wherein R¹, R², R³ and n are defined above, R' is alkyl, heteroalkyl (OR'', SR''', NR''R''' wherein R'' and R''' are alkyl groups), halo substituent at *ortho*, *meta*, or *para* -position to oxygen atom, R is alkyl, aryl, or alkylaryl groups, and n is from zero to five, is outlined in **Scheme 2**. The meta-tyrosine-dipeptide **2a** is coupled to an alkenyl carboxylic acid in the presence of HOObt, EDCI-HCl and NMM. Hydroboration of the resulting product affords compound **2c**. The macrocyclization is achieved under Mitsunobu conditions by using triphenylphosphine and ADDP. (The *Mitsunobu* reaction is reviewed by D. L. Hughes, *Org. Reactions*, **42** (1992) 335, John Wiley & Sons, New York, L. Paquette, ed.). After the ester is hydrolyzed to an acid with
 10
 15 lithium hydroxide, it is coupled to an amine intermediate to afford **2e**.

Scheme 3:

The preparation of compounds of formula **3e** wherein R' , R^1 , R^2 , R^3 , R and n are defined in **Scheme 1** and PG is Cbz, Boc, or alloc is outlined in **Scheme 3**. The compound **3a** was coupled with substituted histidine derivative using DCC. This compound **3b** was deprotected and further treated with ω -bromo acids to obtain compound of the type **3c**. Cyclization of **3c** was accomplished with NaI and Na_2CO_3 in boiling methylvinyl ketone to afford **3d**. The compound **3d** was converted to compounds of type **3e** by hydrolysis of the ester followed by coupling with the appropriate amine intermediate.

Scheme 4:


- 5 The preparation of the compounds of type **4f** where in R' , R^1 , R^2 , R^3 , R , n and PG are defined in **Scheme 1** was initiated from compound of the type **4a**. The alcohol of **4a** was converted to **4b** by treatment with phosgene. **4b** was converted to **4c** by coupling with alloc protected **1b** and Et_3N . The alloc group of **4c** was deprotected using $Pd(PPh_3)_4$ to obtain **4d** which underwent cyclization under the Mitsunobu conditions to yield **4e**. The ester of **4e** was hydrolyzed and further coupled with an amine using $EDCl$, $HOObt$ to obtain compounds of the type **4f**.
- 10

Scheme 5:

- 5 The preparation of compounds of type **5h** wherein R¹, R², R³, R', PG and n are defined in **Schemes 1-3** and PG¹ being Cbz or Boc and PG² being alloc, began with the known compound **5a**. The acid **5a** was converted to the ester by refluxing it with ROH and TsOH. The phenolic oxygen of **5b** was converted to the alloc group by the treatment with alloc-chloride and triethyl amine to yield **5c**. The
- 10 secondary alcohol of **5c** was converted to compounds of type **5d** by coupling with protected cyclohexyl glycine using DCC and HOBT. The alloc group of compound

5d was deprotected using $\text{Pd}(\text{Ph}_3\text{P})_4$, and dimedone. 5e was deprotected and treated with EDCI, HOObt and appropriately activated ruthenium complex to obtain compounds of the formula of 5f. The compounds of the type 5f were converted to cyclic compounds of the formula 5g by the use of Cs_2CO_3 , and subsequent photolytic removal of ruthenium. The ester group of 5g was hydrolyzed and coupled to an amine intermediate to obtain compounds of the type 5h.


Scheme 6:




The preparation of the compound of formula 6f, wherein R^1 , R^2 , R^3 are defined above, R' is alkyl, heteroalkyl (OR'' , SR''' , $\text{NR}''\text{R}'''$ wherein R'' and R''' are alkyl groups), halo substituent at *ortho*, *meta*, or *para*-position, R is alkyl, aryl, or alkylaryl groups, PG is Cbz or Boc, and n is from zero to five, is outlined in Scheme 6. The *meta*-iodophenylglycine 6a is converted to its ester under usual

esterification conditions (ROH, HCl). The product is then coupled to an *N*-protected amino acid in the presence of HOObt, EDCI-HCl and NMM. After deprotection, the resulting amine is coupled again to a terminal alkenyl carboxylic acid to give product **6d**. The intramolecular Heck reaction with a palladium catalyst provides the desired macrocyclic compound **6e**. (The Heck reaction has been reviewed in detail by R. F. Heck, *Org. React.*, 27 (1989) 345-390.). After the ester is hydrolyzed to an acid with lithium hydroxide, it is coupled to an amine intermediate to afford **6f**.


Scheme 7:



The preparation of the compound of formula **7b**, wherein R^1 , R^2 , R^3 are defined above, R' is alkyl, heteroalkyl (OR'' , SR''' , $NR''R'''$ wherein R'' and R''' are alkyl groups), halo substituent at *ortho*, *meta*, or *para* -position, R is alkyl, aryl, or alkylaryl groups, and n is from zero to five, is outlined in **Scheme 7**. The hydrogenation of the double bond of **6e** gave the macrocycle **7a**. Hydrolysis of the ester to acid and subsequent coupling with an amine intermediate afforded **7b**.

Scheme 8:


- 5 The preparation of the compound of formula **8f**, wherein R^1 , R^2 , R^3 are defined above, R' is alkyl, heteroalkyl (OR'' , SR''' , $NR''R'''$ wherein R'' and R''' are alkyl groups), halo substituent at *ortho*, *meta*, or *para*-position to oxygen atom, R is alkyl, aryl, or alkylaryl groups, PG is Boc, and n is from zero to five, is outlined in **Scheme 8**. The *meta*-tyrosine-dipeptide **8a** is coupled to a terminal *N*-protected amino alcohol **8b** under Mitsunobu conditions (triphenylphosphine and ADDP).
- 10 The protecting groups are removed to give diamine hydrochloride **8d**. The macrocyclization is achieved by forming the urea linkage using phosgene or carbonyl diimidazole. The resulting ester is then hydrolyzed to an acid with lithium hydroxide and is subsequently coupled to an amine intermediate to afford the
- 15 desired product **8f**.

Scheme 9:


The synthesis of compounds of the type **9d** wherein the substituents R^1 , R^2 , R^3 , R' , R and PG are defined in **Scheme 1**, was initiated by the deprotection of **9a** with HCl in dioxane and coupling with ω -hydroxy acid using EDCI, HOObt to yield compounds of the type **9b**. The compounds of the type **9b** were further cyclized using Ph_3P , ADDP to generate compounds of the type **9c**. The cyclic compound **9c** was deprotected and coupled with an appropriate amine intermediate to generate compound of type **9d**.

Scheme 10:


48




The synthesis of the compounds of the type 10i wherein R^2 , R^1 , R^1 , R^3 are defined in **Scheme 1**. PG^1 and PG^2 are defined as protecting groups namely Fmoc and Dde. P is defined as a polymer support wherein the compound is immobilized, and n is a number from 1-6. The methodology used for the synthesis of molecules of type 10i is a standard solid phase peptide synthesis with Fmoc protecting group. Fmoc protected Sasarin resin 10a is first deprotected by the treatment of piperidine followed by coupling with the Fmoc protected amino acid using HATU to obtain compound of type 10b. The protecting group of 10b was removed and coupled with amino acid to using HATU to obtain 10c. The polymer supported 10c was deprotected by treatment with piperidine and coupled with hydroxy acid to obtain hydroxy amide of type 10d. The protecting group of 10d was cleaved and coupled with protected lysine derivative using HATU to obtain compounds of type 10e. The protecting group of 10e was once again deprotected and coupled with Fmoc protected amino acid to obtain compound of the type 10f. The protecting groups PG^1 and PG^2 were removed and cyclized using a diacid and HATU to obtain the macrocycle 10g. The compound of 10g was oxidized using Dess-Martin reagent and finally cleaved from the resin using TFA to obtain compound 10i.

Scheme 11:


The synthesis of the compounds of type **11e** wherein R^1 , R^2 , R^3 , R^4 and n are defined in **Scheme 1** and PG^2 is Cbz, PG^1 is Bn and PG is Boc, was initiated from protected acid **11a**. **11a** was converted to compounds of type **11b** by coupling with lysine derivative using EDCI, HOObt methodology. The ester group of **11b** was hydrolyzed using LiOH.H₂O followed by the coupling with an appropriate amine intermediate to obtain the compound **11c**. This was further treated with HCl in dioxane and coupled with lysine intermediate using EDCI, HOObt to form compounds of the type **11d**. The compounds **11d** were deprotected and cyclized using EDCI, HOObt to form compounds of type **11e**.

Preparation of Intermediates:Intermediate A:Step 1:


5 To a stirred solution of 1-nitrobutane (16.5 g, 0.16 mol) and glyoxylic acid in H₂O (28.1 g, 0.305 mol) and MeOH (122 mL) at 0°C-5°C, was added dropwise triethyl amine (93 mL, 0.667 mol) over 2 hrs. The solution was warmed to room temperature, stirred overnight and concentrated to dryness to give an oil. The oil was then dissolved in H₂O and acidified to pH =1 with 10% HCl, followed by
10 extraction with EtOAc. The combined organic solution was washed with brine, dried over Na₂SO₄, filtered and concentrated to dryness to give the product **ii** (28.1 g, 99% yield).

Step 2:

15 To a stirred solution of starting material **ii** (240 g, 1.35 mol) in acetic acid (1.25 L) was added 10% Pd/C (37 g). The resulting solution was hydrogenated at 59 psi for 3 hrs and then at 60 psi overnight. The acetic acid was then evaporated and azeotroped 3 times with toluene, then triturated with MeOH and ether. The solution was then filtered and azeotroped twice with toluene to give **iii** as an off
20 white solid (131 g, 0.891 mol, 66%).

Step 3:


To a stirred solution of the amino acid **iii** (2.0 g, 013.6 mmol) in dioxane (10 mL) and H₂O (5mL) at 0°C, was added 1N NaOH solution (4.3 mL, 14.0 mmol). The resulting solution was stirred for 10 minutes, followed by addition of di-*t*-butyldicarbonate (0.110 g, 14.0 mmol) and stirred at 0 °C for 15 minutes. The solution was then warmed to room temperature, stirred for 45 minutes and kept in refrigerator overnight and concentrated to dryness to give a crude material. To the solution of this crude material in EtOAc (100 mL) and ice, was added KHSO₄ (3.36 g) and H₂O (32 mL) and stirred for 4-6 minutes. The organic layer was then separated and the aqueous layer was extracted twice with EtOAc and the combined organic layer was washed with water, brine, dried over Na₂SO₄, filtered and concentrated to dryness to give the product **iv** as a clear gum (3.0 g, 89% yield).

Step 4:

To a stirred solution of **iv** (3.00 g, 12.0 mmol) in DMF (15 mL) and CH₂Cl₂ (15 mL) at -20°C was added HOObt (1.97 g, 12.0 mmol), *N*-methyl morpholine (4.0 mL, 36.0 mmol) and EDCI (2.79 g, 14.5 mmol) and stirred for 10 minutes, followed by addition of HCl·H₂N-Gly-OBn (2.56 g, 13.0 mmol). The resulting solution was stirred at -20°C for 2 hrs, then kept in refrigerator overnight and


concentrated to dryness, followed by dilution with EtOAc (150 mL). The EtOAc solution was then washed twice with saturated NaHCO₃, H₂O, 5% H₃PO₄, brine, dried over Na₂SO₄, filtered and concentrated to dryness to give the product **v** (4.5 g, 94%). LRMS m/z MH⁺= 395.1.

5 Step 5:



The solution of starting material **v** (7.00 g, 17.8 mmol) in absolute ethanol (300 mL) was stirred at room temperature under a hydrogen atmosphere in the presence of Pd-C (300 mg, 10%). The reaction progress was monitored by tlc. After 2h, the mixture was filtered through a celite pad and the resulting solution was concentrated *in vacuo* to give the product **vi** (5.40 g, quantitative). LRMS m/z MH⁺= 305.1.


Step 6:



To a solution of dimethylamine hydrochloride (1.61 g, 19.7 mmol), N-Boc-phenylglycine (4.50 g, 17.9 mmol), HOObt (3.07 g, 18.8 mmol) and EDCI (4.12 g, 21.5 mmol) in anhydrous DMF (200 mL) and CH₂Cl₂ (150 mL) at -20°C was added NMM (5.90 mL, 53.7 mmol). After being stirred at this temperature for 30 min, the reaction mixture was kept in a freezer overnight (18 h). It was then allowed to warm to rt, and EtOAc (450 mL), brine (100 mL) and 5% H₃PO₄ (100 mL) were added. After layers were separated, the organic solution was washed with 5% H₃PO₄ (100 mL), saturated aqueous sodium bicarbonate solution (2 X


150 mL), water (150 mL), and brine (150 mL), dried (MgSO_4), filtered and concentrated *in vacuo* to afford crude product **viii** (4.86 g) as a white solid, which was used without further purification.

Step 7:




The *N*-Boc-phenylglycine dimethylamide **viii** (4.70 g, crude) was dissolved in 4 N HCl (60 mL, 240 mmol) and the resulting solution was stirred at room temperature. The progress of the reaction was monitored by TLC. After 4 h, the solution was concentrated *in vacuo* to yield **ix** as a white solid which was used in the next reaction without further purification. LRMS m/z MH^+ = 179.0.


Step 8:



The desired compound **x** was prepared according to the coupling procedures described in Step 4. LRMS m/z MH^+ = 465.1.

Step 9:

The desired intermediate **A** was prepared from tripeptide **x** according to the
 5 procedures described in Step 7. LRMS m/z $MH^+ = 365.1$.


Intermediate B:Step 1:

10 The desired product **xii** was obtained by the procedure described for
 Intermediate **A**, Step 8 using commercially available **xi** as the coupling partner.
 The crude material was sufficiently pure for further studies. A portion of the

product was purified by flash chromatography using 97/3 dichloromethane/MeOH.

HRMS (FAB) Calcd for $C_{25}H_{40}N_3O_7$: 494.2866 (M+H)⁺. Found: 494.2863.


Step 2



- 5 The desired product **B** was obtained by the procedure described for Intermediate **A**, Step 7. The crude material was used without further purification.


Intermediate C:

Step 1:




- 10 The desired compound **xiii** was prepared according to the coupling procedures described in Step 6 for intermediate **A**.

Step 2:




The desired compound **xiv** was prepared according to the procedures described in Step 7 for intermediate **A**.

Step 3:




5 The desired compound **xv** was prepared according to the coupling procedures described in Step 6 for intermediate **A**. LRMS m/z MH⁺ = 451.1.


58

Step 4:

The desired intermediate **C** was prepared according to the procedures described in Step 7 for intermediate **A**. LRMS m/z $MH^+ = 351.1$. It was used without further purification.


Intermediate D:

The desired intermediate **D** was prepared from compound **v** according to the procedures described in Step 7 for intermediate **A**. It was used without further purification.

Intermediate E:**Step 1:**


5

The desired product **xviii** was obtained by the procedure described for Intermediate **A**, Step 8 using commercially available **xvii** as the coupling partner. The crude material was sufficiently pure for further studies.

Step 2


10

The desired product **E** was obtained by the procedure described for Intermediate **A**, Step 7. The crude material was used without further purification.

Intermediate F:**Step 1**


5

The desired product **xx** was obtained by the procedure described for Intermediate **A**, Step 4 using commercially available **xix** as the coupling partner. The crude material was sufficiently pure for further studies.



Step 2

10


The desired product **F** was obtained by the procedure described for Intermediate **D**.

Intermediate G:**Step 1**

The desired product **G** was obtained by the procedure described for Intermediate **A**, Step 4 using allylglycine as the coupling partner. The crude material was sufficiently pure. The crude product was treated with 4N HCl/Dioxane and stirred at rt. for 50 min. The reaction mixture was concentrated to dryness to yield intermediate **G** which was used without further purification.

EXAMPLES**Example 1: Preparation of Compound of Formula 1:****Step A:**


A solution of 4-chloropropionic acid (2.0 g, 10.8 mmol) of **1a** in dichloroethane (200 mL) was treated with $\text{CpRu}(\text{CH}_3\text{CN})_3 \text{PF}_6$ (4.7 g, 10.8 mmol, 1.0 equiv) and heated at reflux for 2 h. The reaction mixture was cooled to rt when colorless crystals of the product **1c** precipitated out. The crystals were filtered and washed with 1:1 mixture of $\text{Et}_2\text{O}/\text{CH}_2\text{Cl}_2$ and dried *in vacuo*. The colorless crystals (3.3 g) were analytically pure. ^1H NMR ($\text{CD}_3\text{C}(\text{O})\text{CD}_3$, 400 MHz, ppm, δ , J) 6.77 (d, 2 H, $J = 7.0$ Hz), 6.53 (d, 2 H, $J = 7$ Hz), 5.64 (s, 5 H), 2.87 (t, 2 H, $J = 7.0$ Hz), 2.74 (t, 2 H, $J = 7.0$ Hz); MS: (Electron spray, m/z relative intensity): 350.9 ($\text{C}_{14}\text{H}_{14}\text{ClRu}^+$, M^+ , 100); CHN calcd for $\text{C}_{14}\text{H}_{14}\text{ClF}_6\text{O}_2\text{PRu}$ C=33.92% H=2.85% Cl=7.15% P=6.25% found: C=34.04% H=3.04% Cl=7.09% P=5.71%.

Step B:

A solution of Boc-cyclohexylglycine monohydrate **1d** (6.17 g, 24.00 mmol) in dry CH_2Cl_2 (50.0 mL) was treated with 4-methylmorpholine (2.64 g, 26.0 mmol, 1.1 equiv.) and cooled to -10°C . To this mixture was added isobutyl chloroformate (3.62 g, 3.5 mL, 1.1 equiv.) and the white suspension was stirred until the bath temperature was -5°C . meta-Tyrosine methyl ester hydrochloride salt (6.5 g, 26.5 mmol, 1.1 equiv.) was dissolved in DMF (30 mL) in a separate beaker and treated with 4-methylmorpholine (2.64 g, 26.0 mmol, 1.1 equiv.) and stirred at rt. for 15 min. This mixture was added to the reaction which was accompanied by evolution of CO_2 . The reaction mixture was stirred at rt for 1 h and diluted with 1M aq. HCl (100 mL). The aqueous layer was extracted with ethyl acetate (3x200 mL) and the combined organic layer was extracted with 1M HCl (1x100 mL), aq NaOH

(1x100 mL), brine (1x100 mL), dried (Na_2SO_4), concentrated *in vacuo* and purified by chromatography (SiO_2 , EtOAc/Hexanes 3/7) to yield 5.3 g (53%) of coupled compound **1f** as a colorless foam.


Step C:




5

A solution of **1f** (10g, 23.04 mmol) was dissolved in HCl (4M solution in dioxane, 100 mL) and stirred at rt for 2-4 h. The reaction mixture was concentrated *in vacuo* and the solid was resuspended in ether. It was filtered and the solid was washed with ether which was dried to give a colorless solid **1g** (8.2g, 96%) ^1H NMR ($\text{d}_4\text{-CD}_3\text{OD}$, 400 MHz, δ , ppm) 7.09 (t, 1 H, $J=8.0$ Hz), 6.71-6.36 (m, 3 H), 4.69 (dd, 1H, $J=6.0$ Hz, 3.2 Hz), 3.69 (s, 3 H), 3.66 (d, 1 H, $J=5.2$ Hz), 3.15 -3.10 (dd, 1 H, $J=5.6$ Hz, 4.0 Hz), 1.87-1.69 (m, 6 H), 1.32-1.10 (m, 5 H).

10


Step D:

- 5 A solution of cyclopentadiene- η^6 -4-chlorophenylpropionic acid-ruthenium hexanesafluorophosphate **1c** (2.0g, 4.0 mmol) in DMF (20 mL) was treated with HOBT (810 mg, 6.0 mmol, 1.5 equiv) and Hünigs base (2.6 g, 16.0 mmol, 4.0 equiv.) The reaction mixture was cooled to 0° C and treated with EDCI•HCl (888 mg, 5.0 mmol, 1.25 equiv.) The reaction mixture was stirred at 0 °C for 30 min and
- 10 amine salt **1g** (1.48 g, 4.0 mmol) was added to the mixture and stirred at rt for 12 h. The reaction mixture was concentrated *in vacuo* and the residue was diluted with H₂O (200 mL) and extracted into CH₂Cl₂ (3x100 mL). The combined organic layers were extracted with aq. HCl (1x100 mL), NaHCO₃ (1x100 mL), brine (1x100 mL) and dried (Na₂SO₄), filtered concentrated *in vacuo* and the brown
- 15 solid **1h** was used for cyclization without any further purification.


Step E:

A solution of cyclopentadiene- η 6-ruthenium-4-chlorophenylpropionic acid-
 5 cyclohexylglycine-*meta*-tyrosine-OCH₃ **1h** (1.47 g crude) in dry DMF (150 mL) was
 treated with Cs₂CO₃ (2.40 g, 7.37 mmol, 5.0 equiv) and degassed by bubbling
 dry N₂ into the reaction mixture. The reaction mixture was stirred at rt for 16 h and
 the excess DMF was distilled off. The residue was dissolved in H₂O (200 mL) and
 extracted with CH₂Cl₂ (3x100 mL). The combined organic layer was extracted
 10 with brine (100 mL), dried (Na₂SO₄), filtered concentrated *in vacuo* and the
 residue was used for photolytic decomplexation of ruthenium without further
 purification.

The crude ruthenium complex was dissolved in acetonitrile (35 mL),
 degassed and photolysed in a Raynot ($\lambda=350$ nm) for 48 h. The reaction mixture
 15 was concentrated *in vacuo* and the residue was purified by chromatography
 (SiO₂, EtOAc/Hexanes 7:3) to yield 360 mg (52%) of a colorless solid **1i**.

Step F:


- 5 A solution of biphenyl ether **1i** (300 mg, 0.65 mmol) in CH₃OH (10 mL), CH₂Cl₂ (20 mL) and H₂O (5 mL) was treated with LiOH•H₂O (90mg, 2.2 mmol, 3.4 equiv.) and stirred at rt for 2 h. The reaction mixture was acidified with aq. HCl (6 M) and extracted into CH₂Cl₂ (3x30 mL). The combined organic layers were dried (Na₂SO₄), filtered, and concentrated *in vacuo* to yield colorless acid **1j** (200 mg, 66%).
- 10

Step G:



A solution of acid **1j** (100 mg, 0.22 mmol) in dry DMF (2.5 mL) was treated with HOOBt (45 mg, 0.33 mmol) and Hünig's base (141 mg, 1.1 mmol, 5.0 equiv.)

The reaction mixture was cooled to 0° C and treated with EDCI (63 mg, 0.33 mmol, 1.5 equiv) and stirred for 20 min. The reaction mixture was treated with amine B (118 mg, 0.27 mmol, 1.22 equiv.) and stirred at rt for 12 h. The reaction mixture was concentrated *in vacuo* and diluted with H₂O (30 mL). The aqueous layer was extracted with CH₂Cl₂ (3x50 mL) and EtOAc (3x50 mL). The combined organic layers were extracted with aq. HCl (2M), aq. NaOH (2M), dried (Na₂SO₄) filtered concentrated *in vacuo* to obtain a colorless solid **1k** (79 mg) which was used for oxidation. MS: (Electron spray, *m/z rel int*): 826 [(M+1)⁺, 100], 494 (20), 94 (30).



Step H:



A solution of hydroxy amide **1k** (130 mg, 0.16 mmol) in DMF (2.0 mL) was treated with Dess-Martin reagent (130 mg, 0.32 mmol, 2.0 equiv.). The reaction mixture was stirred at rt for 2 h and the mixture was concentrated *in vacuo*. The residue was purified by chromatography (SiO₂, CH₃OH/CH₂Cl₂: 1:49) to yield oxidized product **1** (55 mg, 42%) as a colorless solid. MS: (Electron spray, *m/z rel int*): 858 [(M+CH₃OH+1)⁺, 100], 824 [(M+1)⁺, 63].

Example 2: Preparation of Compound of Formula 2:**Step A:**

A solution of *tert*-butyl ester **1** (50.0 mg, 60.0 μmol) was treated with TFA/ CH_2Cl_2 (1:1, 4 mL) and stirred at rt for 2 h. The disappearance of the ester to the base line was followed by TLC ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ 1:24). After the deprotection was complete the reaction mixture was concentrated *in vacuo* and the residue was repeatedly treated with heptanes (4.0 mL) and concentrated to yield a white solid **2** (49 mg, 100%). MS: (Electron spray, m/z rel int): 768 [(M+1)⁺, 100].


Example 3: Preparation of Compound of Formula 3:**Step A:**

A solution of acid **1j** (100 mg, 0.22 mmol) in dry DMF (2.5 mL) was treated with HOObt (45 mg, 0.33 mmol) and Hünig's base (141 mg, 1.1 mmol, 5.0 equiv.)

10 The reaction mixture was cooled to 0° C and treated with EDCI (63 mg, 0.33 mmol, 1.5 equiv) and stirred for 20 min. The reaction mixture was treated with amine **E** (79 mg, 0.27 mmol, 1.22 equiv.) and stirred at rt for 12 h. The reaction mixture was concentrated *in vacuo* and diluted with H₂O (30 mL). The aqueous layer was extracted with CH₂Cl₂ (3x50 mL). The combined organic layers were



15 extracted with aq. HCl (1M, 30 mL) aq. NaOH (1M, 30 mL), dried (Na₂SO₄)

filtered concentrated *in vacuo* to obtain a colorless solid **3a** (58 mg) which was used for oxidation. MS: (Electron spray, *m/z rel int*): 693 [(M+1)⁺, 100], 637 (41), 494 (55), 394 (51), 338 (13).



Step B:

A solution of alcohol **3a** (95 mg, 0.14 mmol) in CH₂Cl₂ (2.0 mL) was treated with Dess-Martin reagent (116 mg, 0.28 mmol, 2.0 equiv.) The reaction mixture was stirred at rt for 2 h and the mixture was concentrated *in vacuo*. The residue was purified by chromatography (SiO₂, CH₃OH/CH₂Cl₂ 1:32) to yield oxidized product **3** (47 mg, 42%) as a colorless solid. MS: (Electron spray, *m/z rel int*): 691 (M+1)⁺.

10


Example 4: Preparation of Compound of Formula 4:**Step A:**

A solution of *tert*-butyl ester 3 (47.0 mg, 68.0 μmol) was treated with HCl (4M Dioxane, 5 mL) and stirred at rt for 25 h. The disappearance of the ester to the base line was followed by TLC ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ 1:24). After the deprotection was complete the reaction mixture was concentrated *in vacuo* and the residue was repeatedly treated with heptanes (5.0 mL) and concentrated to yield a white solid 4 (43 mg, 100%). MS: (Electron spray, m/z rel int): 635 [(M+1)⁺, 100], 465 (62), 336 (62).


Example 5: Preparation of Compound of Formula 5:**Step A:**

A solution of 4-chlorobutyric acid **5a** (3.0g, 15.10 mmol) in dichloroethane (200 mL) was treated with $\text{CpRu}(\text{CH}_3\text{CN})_3\text{PF}_6$ **1b** (6.6 g, 15.10 mmol, 1.0 equiv) and heated at reflux for 2.5 h. The reaction mixture was cooled to 0°C and filtered. The filtrate was concentrated *in vacuo* and dissolved in CH_3CN (10 mL) and treated with a large excess of Et_2O . The gum separating out was separated by decanting the ether and the residue was dissolved in $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ (1:1, 100 mL) and concentrated *in vacuo* to obtain **5b** as a brown gum which solidifies (3.5 g, 46%).

Step B:




A solution of carboxylic acid **5b** (3.12 g, 5.95 mmol) in dry DMF (20 mL) was treated with Hünigs base (3.07 g, 24.0 mmol, 4.0 equiv, 4.4 mL) and HOBt (1.2 g, 8.93 mmol, 1.5 equiv). The reaction mixture was cooled to 0°C and the treated with EDCI (1.35 g, 7.43 mmol, 1.25 equiv) and stirred for 1h. To this reaction mixture was added amine hydrochloride **1g** (2.65g, 7.14 mmol, 1.2 equiv), and the reaction mixture was stirred at rt for 12 h. DMF was distilled out and the residue was diluted with water and the aqueous layer was extracted with CH₂Cl₂. The combined organic layers were extracted with aq NaHCO₃, aq. HCl, brine, dried (Na₂SO₄), filtered, concentrated *in vacuo* and the crude product **5c** (4.3 g) was used for cyclization without further purification. ¹H NMR (d₄-CD₃OD, 400 MHz, δ, ppm) 7.35 (t, 1H), 6.72-6.60 (m, 5 H), 6.33-6.20 (dd, 2 H), 5.51 (s, 5 H), 4.19 (d, 1 H), 3.68 (s, 3 H), 3.19-2.83 (m, 2 H), 2.51-2.40 (m, 2 H), 2.40-2.25 (m, 2 H), 1.99-1.59 (m, 8 H), 1.35-0.98 (m, 5 H); MS (FAB, NBA-G/TG-DMSO, *m/z* relative intensity) 695.3 ([M-PF₆]⁺, 100), 232 (20), 171(30); HRMS calcd for C₃₄H₄₂N₂O₅ClRu⁺ (M-PF₆)⁺ 695.1832; found 695.1845.

Step C:


A solution of chloro-compound **5c** (3.0 g 3.6 mmol) in dry DMF (300 mL) was degassed with dry N₂ and Cs₂CO₃ (5.2 g, 16 mmol, 4.0 equiv) and stirred at rt. for 16h. The solvent DMF was distilled off and the residue was diluted with water and extracted with CH₂Cl₂ (3x100 mL). The combined organic layers were dried (Na₂SO₄), filtered, concentrated *in vacuo* and dried under vacuum overnight. It was used for photolytic removal of Ru without further purification. MS FAB (NBA-G/TG-DMSO 695 [(M-PF₆)⁺, 100].

The cyclized compound from the previous step was dissolved in CH₃CN (35mL) and photolysed in a Raynot ($\lambda=350$ nm) for 48h. The reaction mixture was concentrated *in vacuo* and the residue was purified by chromatography (SiO₂, EtOAc/Hexanes 1:1) to yield a tan colored solid **5d** (600 mg, 34%). ¹H NMR (CDCl₃, 400 MHz, δ , ppm) 7.58 (d, 1H, $J=7.6$ Hz), 7.14 (t, 1 H, $J=8.0$ Hz), 6.94 (d, 2 H, $J=8.4$ Hz), 6.87 (dd, 1 H, $J=2.4, 5.6$ Hz), 6.73 (d, 1 H, $J=7.2$ Hz), 6.59 (s, 1 H), 6.57 (s, 2 H), 6.39 (d, 1 H, $J=8.0$ Hz), 4.51 (dt, 1 H, $J=2.8, 8.0$ Hz), 3.80-3.62 (m, 1 H), 3.62 (s, 3 H), 3.05-3.00 (dd, 1H, $J=2.8, 11.6$ Hz), 2.85 (dd, 1 H, $J=8.4, 6.0$ Hz), 2.76-2.72 (m, 1 H), 2.36-2.19 (m, 3 H), 2.02 (dd, 1 H, $J=6.4, 9.2$ Hz), 1.8-1.73 (m, 1 H), 1.61-1.34(m, 7H), 1.41-0.71 (m, 7 H). MS (FAB, NBA-G/TG-DMSO, m/z relative intensity), 493 [(M+1)⁺, 100], 465 (20), 232 (30), 171 (40); HRMS calcd. for C₂₉H₃₇N₂O₅ (M+1)⁺: 493.2702; found 493.2699.

75


Step D:

A solution of ether **5d** (200 mg, 0.42 mmol) in CH₃OH (5 mL), CH₂Cl₂ (10 mL) and H₂O (0.5 mL) was treated with LiOH•H₂O (18 mg, 0.44 mmol, 1.1 equiv.) and stirred at rt for 12 h. The reaction mixture was acidified with aqueous HCl (12 N, 1 mL) and concentrated *in vacuo* to yield acid **5e** which was used directly for the coupling without further purification.



Step E:

A solution of acid **5e** in dry DMF (5.0 mL) was treated with HOObt (103 mg, 0.63 mmol, 1.5 equiv.), Hünigs base (216 mg, 1.68 mmol, 4.0 equiv.) and amine **B** (270 mg, 0.63 mmol, 1.47 equiv.) The reaction mixture was cooled to 0°


C and treated with EDCI (101 mg, 0.52 mmol, 1.25 equiv) and stirred at rt for 12 h. The reaction mixture was concentrated *in vacuo* and diluted with H₂O (30 mL). The aqueous layer was extracted with CH₂Cl₂ (3x50 mL) and EtOAc (3x50 mL). The combined organic layers were extracted with aq. HCl (2M) aq. NaOH (2M), dried (Na₂SO₄) filtered concentrated *in vacuo* to obtain a colorless solid **5f** (177 mg) which was used for oxidation. MS: (Electron spray, *m/z rel int*): 840 [(M+1)⁺, 100], 394 (100).

Step F:

A solution of alcohol **5f** (177 mg, 0.21 mmol) in CH₂Cl₂ (10.0 mL) was treated with Dess-Martin reagent (178 mg, 0.42 mmol, 2.0 equiv.) The reaction mixture was stirred at rt for 3 h and the mixture was concentrated *in vacuo*. The residue was purified by chromatography (SiO₂, CH₃OH/CH₂Cl₂ 1:49) to yield oxidized product **5** (23 mg, 13%) as a colorless solid. MS: (Electron spray, *m/z rel int*): 870 [(M+CH₃OH+1)⁺, 50], 838 [(M+1)⁺, 100].

Example 6: Preparation of Compound of Formula 6:**Step A:**

A solution of *tert*-butyl ester 5 (50.0 mg, 60.0 μmol) was treated with TFA/ CH_2Cl_2 (1:1, 4 mL) and stirred at rt for 7 h. The disappearance of the ester to the base line was followed by TLC ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ 1:24). After the deprotection was complete the reaction mixture was concentrated *in vacuo* and the residue was repeatedly treated with heptanes (4.0 mL) and concentrated to yield a white solid 6 (14 mg, 100%). MS: (Electron spray, m/z *rel int*): 782 [(M+1)⁺, 100].

Example 7: Preparation of Compound of Formula 7:


7

Step A:


7a

7b

A solution of alcohol **7a** (9.2g, 54.1 mmol) in dry CH_2Cl_2 (200 mL) was treated with DMSO (35 mL) and Et_3N (16.4g, 16.3 mmol, 23.4 mL). The reaction mixture was cooled to 0°C and treated with $\text{Py}\cdot\text{SO}_3$ (12.9 g, 81.2 mmol, 1.50 equiv.) dissolved in DMSO (30 mL). The reaction mixture was stirred at 0°C for 0.5 h and rt for 6 h. The reaction mixture was concentrated *in vacuo* and diluted with Et_2O (100 mL) and H_2O (200 mL). The layers were separated and the aqueous layer was extracted with Et_2O (3x100 mL). The combined organic layers were extracted with HCl (2M, 3x100 mL), brine (1x100 mL) concentrated *in vacuo* and purified by chromatography (SiO_2 , EtOAc/Hexanes 1:7) to yield aldehyde **7b** which solidified to a waxy solid on standing (7.1g, 77%). CHN calcd for $\text{C}_9\text{H}_9\text{ClO}$: C=64.11% H=5.38%; found: C=64.08% H=5.30%.


Step B:

A solution of thiethylphosponoacetate (6.72g, 30 mmol, 1.2 equiv) in dry THF (100 mL) was treated with NaH (60% dispersion, 1.5g, 35 mmol, 1.4 equiv) at 0°C. The reaction mixture was stirred at 25°C for 1 h until the H₂ evolution ceased. A solution of aldehyde **7b** (4.2g, 25.0 mmol) in dry THF (5.0 mL) was added and the reaction mixture was stirred for 36 h. The reaction mixture was diluted with H₂O (100 mL) and extracted with Et₂O (3x70 mL). The combined organic layer was dried (MgSO₄), filtered, concentrated *in vacuo* and chromatographed to yield α,β-unsaturated ester **7c** (4.2g, 71%) which was used for reduction.

Step C :


A solution of α,β-unsaturated ester **7c** (4.2g, 8.0 mmol) in EtOAc (50 mL) was treated with Pd/C (10% w/w, 500 mg) and hydrogenated at 50 psi for 12 h. The reaction mixture was filtered through a plug of celite and the filtrate was concentrated *in vacuo* to yield the reduced compound **7d** (3.9 g, 93%).

Step D:



A solution of the ester **7d** (3.9 g, 16.2 mmol) in CH₃OH/THF/H₂O (1:1:0.1, 110 mL) was treated with LiOH•H₂O (1.2 g, 30 mmol, 2.0 equiv) and stirred at rt for 5 h. The reaction mixture was concentrated *in vacuo* and the residue was diluted with H₂O (100 mL) and extracted into Et₂O (3x50 mL). The aqueous layer was acidified to pH ~1 (13 M HCl) and the turbid aqueous layer was extracted with Et₂O (3x100 mL). The combined organic layers were dried (MgSO₄) filtered concentrated *in vacuo* to yield a colorless solid **7e** (3.1g, 96%). CHN calcd for C₁₁H₁₃ClO₂ C=62.12% H=6.16%; found: C=62.27% H=6.23%.


Step E:



A solution of 4-chlorophenyl pentanoic acid **7e** (3.0g, 14.15 mmol) in dichloroethane (150 mL) was treated with CpRu(CH₃CN)₃PF₆ **1b** (6.75 g, 15.10 mmol, 1.0 equiv) and heated at reflux for 2.5 h. The reaction mixture was cooled to 0° C and filtered. The filtrate was concentrated *in vacuo* and dissolved in CH₃CN (20 mL) and treated with a large excess of Et₂O. The gum separating out was separated by decanting the ether and the residue was dissolved in CH₂Cl₂/CH₃OH (1:1, 100 mL) and concentrated *in vacuo* to obtain **7f** a brown

gum which solidifies (4.36 g, 58%). MS: (Electron spray, m/z rel int): 379 [(M-PF₆)⁺, 100].


Step F:



- 5 A solution of carboxylic acid **7f** (3.12 g, 5.95 mmol) in dry DMF (20 mL) was treated with Hünigs base (3.07 g, 24.0 mmol, 4.0 equiv, 4.4 mL) and HOBt (1.2 g, 8.93 mmol, 1.5 equiv). The reaction mixture was cooled to 0°C and the treated with EDCI (1.35 g, 7.43 mmol, 1.25 equiv) and stirred for 1h. To this reaction mixture was added amine hydrochloride **1g** (2.65g, 7.14 mmol, 1.2 equiv) was added and the reaction mixture was stirred at rt for 12 h. The DMF was distilled out and the residue was diluted with water and the aqueous layer was extracted with CH₂Cl₂. The combined organic layers were extracted with aq NaHCO₃, aq. HCl, brine, dried (Na₂SO₄) filtered concentrated *in vacuo* and the crude product **7g** (4.3 g) was used for further cyclization without purification. ¹H NMR (d₄-
- 10 CD₃OD, 400 MHz, δ, ppm) 7.35 (t, 1H), 6.72-6.60 (m, 5 H), 6.33-6.20 (dd, 2 H), 5.51 (s, 5 H), 4.19 (d, 1 H), 3.68 (s, 3 H), 3.19-2.83 (m, 2 H), 2.51-2.40 (m, 2 H), 2.40-2.25 (m, 2 H), 1.99-1.59 (m, 8 H), 1.35-0.98 (m, 5 H); MS (FAB, NBA-G/TG-

DMSO, m/z relative intensity) 695.3 ($[M-PF_6]^+$, 100), 232 (20), 171 (30); HRMS calcd for $C_{34}H_{42}N_2O_5ClRu^+$ ($M-PF_6$) 695.1832; found 695.1845.

Step G:



5

A solution of chloro-compound **7g** (3.0 g 3.6 mmol) in dry DMF (300 mL) was degassed with dry N_2 and Cs_2CO_3 (5.2 g, 16 mmol, 4.0 equiv) and stirred at rt. for 16h. The solvent DMF was distilled off and the residue was diluted with water and extracted with CH_2Cl_2 (3x100 mL). The combined organic layers were
 10 dried (Na_2SO_4) filtered, concentrated *in vacuo* and dried in vacuum overnight. It was used for photolytic removal of Ru without further purification. MS FAB (NBA-G/TG-DMSO 695 ($[M-PF_6]^+$, 100).


The cyclized compound from the previous step was dissolved in CH_3CN (35mL) and photolysed in a Raynot ($\lambda=350$ nm) for 48 h. The reaction mixture was
 15 concentrated *in vacuo* and the residue was purified by chromatography (SiO_2 , EtOAc/Hexanes 1:1) to yield a tan colored solid **7h** (600 mg, 34%). 1H NMR ($CDCl_3$, 400 MHz, δ , ppm) 7.58 (d, 1H, $J=7.6$ Hz), 7.14 (t, 1 H, $J=8.0$ Hz), 6.94 (d, 2 H, $J=8.4$ Hz), 6.87 (dd, 1 H, $J=2.4, 5.6$ Hz), 6.73 (d, 1 H, $J=7.2$ Hz), 6.59 (s, 1 H), 6.57 (s, 2 H), 6.39 (d, 1 H, $J=8.0$ Hz), 4.51 (dt, 1 H, $J=2.8, 8.0$ Hz), 3.80-3.62 (m, 1 H), 3.62 (s, 3 H), 3.05-3.00 (dd, 1H, $J=2.8, 11.6$ Hz), 2.85 (dd, 1 H, $J=8.4, 6.0$ Hz), 2.76-2.72 (m, 1 H), 2.36-2.19 (m, 3 H), 2.02 (dd, 1 H, $J=6.4, 9.2$ Hz), 1.8-1.73 (m, 1 H), 1.61-1.34(m, 7H), ,1.41-0.71 (m, 7 H). MS (FAB, NBA-G/TG-

20

DMSO, *m/z* relative intensity), 493 [(M+1)⁺, 100], 465 (20), 232 (30), 171 (40);

HRMS calcd. for C₂₉H₃₇N₂O₅ (M+1)⁺: 493.2702; found; 493.2699.


Step H:




A solution of ether 7h (220 mg, 0.46 mmol) in CH₃OH (3.0 mL), CH₂Cl₂ (10 mL) and H₂O (0.5 mL) was treated with LiOH•H₂O (18 mg, 0.44 mmol, 1.1 equiv.) and stirred at rt for 12 h. The reaction mixture was acidified with aq.HCl (13 M, 1mL) and concentrated *in vacuo* to yield acid 7i which was used directly

10 for the coupling without further purification.



Step I:





A solution of acid **7i** in dry DMF (3.0 mL) was treated with HOOBt (94 mg, 0.75 mmol, 1.6 equiv.), Hünigs base (237 mg, 1.84 mmol, 4.0 equiv.) and amine **B** (246 mg, 0.58 mmol, 1.47 equiv.) The reaction mixture was cooled to 0° C and treated with EDCI (110 mg, 0.58 mmol, 1.25 equiv) and stirred at 0 °C for 25 min
5 for 12 h. The reaction mixture was concentrated *in vacuo* and diluted with H₂O (30 mL). The combined aqueous layers were extracted with CH₂Cl₂ (3x30 mL). The organic layers were extracted with aq. HCl (1 M, 60 mL) aq. NaOH (60 mL), dried (Na₂SO₄) filtered concentrated *in vacuo* to obtain a colorless solid **7j** (230 mg) which was used for oxidation. MS: (Electron spray, *m/z rel int*): 854 [(M+1)⁺,
10 100], 479 (70), 327 (50), 271.1 (100).

Step J:

A solution of alcohol **7j** (220 mg, 0.26 mmol) in CH₂Cl₂ (3.0 mL) was
15 treated with Dess-Martin reagent (218 mg, 0.51 mmol, 2.0 equiv.) The reaction mixture was stirred at rt and the mixture was concentrated *in vacuo*. The residue was purified by chromatography (SiO₂, CH₃OH/CH₂Cl₂ 1:24) to yield oxidized product **7** (23 mg, 13%) as a colorless solid. MS: (FAB, *m/z, rel. int.*) 852 [(M+1)⁺, 43], 796 (100), 768 (20), 461 (20), 433 (50), 405 (50), 336 (30), 294, (50).


Example 8: Preparation of Compound of Formula 8:**Step A:**

A solution of *tert*-butyl ester **7** (32.0 mg, 37.0 μmol) was treated with TFA/ CH_2Cl_2 (1:1, 5.0 mL) and stirred at rt for 4 h. The disappearance of the ester to the base line was followed by TLC ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ 1:24). After the deprotection was complete the reaction mixture was concentrated *in vacuo* and the residue was repeatedly treated with heptanes/ CH_3OH (4.0 mL) and concentrated to yield a tan solid **8** (29.0 mg, 100%). MS: (Electron spray, m/z *rel int*): 796 $[(M+1)^+, 100]$.

Example 9: Preparation of Compound of Formula 9:**Step A:**

A solution of Boc-Glycine **9a** (1.75g, 10.0 mmol) in dry DMF (50 mL) was treated with HOObt (2.65 g, 15 mmol, 1.5 equiv) and EDCI (2.86g, 15.0 mmol, 1.5 equiv). The reaction mixture was treated with Hünigs base (5.16 g, 40 mmol, 4.0 equiv, 7.3 mL). The reaction mixture was stirred for 1h and *meta*-tyrosine-OCH₃·HCl **1e** (2.5 g, 11.5 mmol, 1.1 equiv.) was added and stirred at 25 °C for 12 h. The reaction mixture was concentrated *in vacuo* and the residue was diluted with aq. NaHCO₃ and extracted into CH₂Cl₂. The combined organic layer were concentrated and the residue purified by chromatography (SiO₂, EtOAc/Hexanes 1:1) to yield a colorless solid **9b** (3.4g, 90%).


Step B:



5 A solution of **9b** (4.6g, 13.06 mmol) in HCl (4M solution in Dioxane, 50 mL) was stirred at rt. for 3h. The reaction mixture was concentrated *in vacuo* and the residue was dried in high vacuum to yield **9c** as a fine powder which was used for the next step. ^1H NMR (CD_3OD , 400 MHz, δ , ppm) 8.67 (d, 1 H, $J=7.9$ Hz), 7.10-7.07 (m, 1 H), 6.68-6.64 (m, 2 H), 4.75-4.70 (m, 1 H), 3.75-3.61 (m, 2 H), 3.66 (s, 3 H), 3.10 (dd, 1 H, $J=5.2, 8.5$ Hz), 2.90 (dd, 1 H, $J=8.8$ Hz, 5.0 Hz).

10


Step C:



A solution of $[\text{CpRu}(\eta^6\text{-4-chlorophenyl)propionic acid}]\text{PF}_6$ **1c** (3.0 g, 46.01 mmol) in dry DMF (60 mL) was treated with HOBt (1.3 g, 9.16 mmol, 1.5 equiv.) and Hünigs base (3.22 g, 4.60 mL, 25.0 mmol, 4.0 equiv.) The reaction mixture

15


was cooled to 0 ° C and treated with EDCI (1.75 g, 9.16 mmol, 1.5 equiv.) The reaction mixture was stirred at 0° C for 30 min and the glycine ammonium salt **9c** (1.75 g, 6.06 mmol, 1.0 equiv.) was added. The reaction mixture was stirred at rt for 12 and the DMF was distilled out *in vacuo*. The residue was diluted with aq. HCl (1M, 100 mL) and extracted into CH₂Cl₂ (3x100 mL). The combined organic layers were extracted with aq. NaHCO₃ (1x100 mL), brine (50 mL), dried (Na₂SO₄), filtered, concentrated *in vacuo* to yield a brown solid **9d** (1.5 g, 34%) which was used for cyclization. MS: (Electron spray, *m/z* relative intensity): 585 [(M-PF₆)⁺, 100], 459 (30), 373 (30), 198 (20).

Step D:

A solution of the ruthenium complex **9d** (1.5 g 2.05 mmol) in dry DMF (100 mL) was degassed with dry N₂ at rt. and Cs₂CO₃ (5.0 g, 15 mmol, 7.5 equiv) was added and stirred at rt. for 12h. The solvent DMF was distilled off and the residue was diluted with water (100 mL) and extracted with CH₂Cl₂ (3x100 mL). The combined organic layers were extracted with brine (100 mL), dried (Na₂SO₄), filtered, concentrated *in vacuo* and dried in vacuum overnight. It was used for photolytic removal of Ru without further purification.


The cyclized compound from the previous step was dissolved in CH₃CN (30 mL) and filtered into a quartz tube. The solution was degassed and photolyzed in a Raynot ($\lambda=350$ nm) for 48h. The reaction mixture was concentrated *in vacuo* and the residue was purified by chromatography (SiO₂, EtOAc) to yield a tan colored solid **9e** (230 mg, 30%). ¹H NMR (CDCl₃, 400 MHz, δ , ppm) 7.23-7.18 (m, 2 H), 7.09-7.01 (m, 3 H), 6.76 (dd, 1 H, *J*=2.4, 8.8 Hz), 6.66

(d, 1 H, $J=7.6$ Hz), 6.47 (d, 1 H, $J=5.6$ Hz), 6.17 (s, 1 H), 5.64 (s, 1 H), 4.69 (q, 1 H, $J=4.4$ Hz), 3.77 (s, 3 H), 3.68-3.51 (m, 2 H), 3.35 (dd, 1 H, $J=4.0, 10.8$ Hz), 3.05 (dd, 1 H, $J=5.2, 9.2$ Hz), 2.96-2.92 (m, 2 H), 2.61-2.56 (m, 1 H), 2.30-2.29 (m, 1 H); ^{13}C NMR : (CDCl_3 , 100 MHz, δ ppm) 172.3, 171.4, 168.1, 159.9, 155.4, 137.6, 136.4, 131.0, 130.0, 129.5, 123.3, 122.4, 121.0, 117.7, 117.1, 53.6, 53.0, 43.6, 39.9, 36.1, 32.3. MS: (Electron spray, m/z relative intensity): 383 $[(M+1)^+$, 100], 279 (20)

Step E:

A solution of cyclic compound **9e** (150 mg, 0.4 mmol) in THF (4.0 mL), H_2O (4.0 mL) was stirred at rt with $\text{LiOH}\cdot\text{H}_2\text{O}$ (41.0 mg, 1.0 mmol, 2.5 equiv) for 3 h. The reaction mixture was acidified with conc. HCl (2.0 mL) and concentrated *in vacuo*. The solid **9f** was dried *in vacuo* and used for further coupling without further purification.

Step F:




5




A solution of the hydrolyzed acid **9f** in dry DMF (4.0 mL) and CH₂Cl₂ (4.0 mL) was treated with HOObt (103mg, 0.58 mmol, 1.5 equiv) and cooled to 0 °C and Hünigs base (206 mg, 1.60 mmol, 4.0 equiv, 295 μL) was added. To this mixture was added EDCI (112 mg, 0.58 mmol, 1.5 equiv) and the reaction mixture was stirred at 0° C for 0.5 h and treated with the amine hydrochloride **B** (206 mg, 0.48 mmol, 1.2 equiv.). The reaction mixture was stored in freezer for 48 h and concentrated *in vacuo* to remove DMF and CH₂Cl₂. The residue was diluted with aq. HCl (2M) and extracted with CH₂Cl₂ (3x50 mL) The combined organic layer was extracted with aq. HCl (1M, 3x50 mL), aq. NaOH (2M) brine (100 mL), dried (Na₂SO₄) and concentrated *in vacuo*. The residue **9g** (200 mg) was oxidized without further purification.

15

Step G:




- 5 A solution of alcohol **9g** (200 mg, 0.27 mmol) in CH₂Cl₂ (3.0 mL) was treated with Dess-Martin reagent (342 mg, 0.81 mmol, 3.0 equiv.). The reaction mixture was stirred at rt for 3 h and diluted with aq. NaHCO₃ and aq. Na₂S₂O₃. The reaction mixture was stirred at rt for 20 min and the reaction mixture was extracted with CH₂Cl₂ (3x30 mL). The combined organic layers were extracted with brine (50 mL), dried (Na₂SO₄), filtered concentrated *in vacuo* and the residue
- 10 was purified by chromatography (SiO₂, CH₃OH (2M NH₃)/CH₂Cl₂ 1:19) to yield ketoamide **9** (100 mg, 50%) of a colorless solid. MS: (Electron spray, *m/z* relative intensity): 742 ([M+1]⁺, 100), 686 (80).

Example 10: Preparation of Compound of Formula 10:**10****Step A:****9****10**


5

A solution of *tert*-butyl ester **9** (100 mg, 0.13 mmol) in dry CH_2Cl_2 (4.0 mL) was treated with TFA (4.0 mL) and stirred at rt. for 5 h. The reaction mixture was concentrated *in vacuo* and the residue was repeatedly dissolved in toluene/ CH_2Cl_2 and concentrated *in vacuo* several times to yield a fine colorless solid **10**. MS (FAB, NBA/DMSO, *m/z* relative intensity), 686 $[(M+1)^+]$, 40], 460 (20), 307 (100), 289 (60); HRMS calcd. for $\text{C}_{36}\text{H}_{40}\text{N}_5\text{O}_9$ $(M+1)^+$: 686.2825; found: 686.2840.

10

Example 11: Preparation of Compound of Formula 11:**11**


5

Step A:**1g****11a**

To a solution of amine hydrochloride **1g** (1.20g, 3.23 mmol), 6-heptenoic acid (0.610 g, 4.68 mmol), HOObt (0.765 g, 4.69 mmol) and EDCI (1.07 g, 5.58 mmol) in anhydrous DMF (50 mL) and CH₂Cl₂ (50 mL) at -20°C was added NMM (1.55 mL, 14.1 mmol). After stirring at this temperature for 30 min, the reaction mixture was kept in a freezer for 18 h. It was then allowed to warm to rt. EtOAc (150 mL), brine (50 mL) and 5% H₃PO₄ (50 mL) were added. After separation, the organic solution was washed with 5% H₃PO₄ (80 mL), saturated aqueous sodium bicarbonate solution (2 X 80 mL), water (80 mL), and brine (80 mL), dried with magnesium sulfate, filtered and concentrated *in vacuo*. Flash chromatography (2 to 5 % MeOH-CH₂Cl₂) afforded **11a** (1.46 g, 3.28 mmol, quant.) as a white solid.

¹H NMR (400 MHz, d₆-DMSO) δ 9.25 (s, 1 H), 8.31 (d, *J* = 7.2 Hz, 1 H), 7.70 (d, *J*


≈ 9.2 Hz, 1 H), 7.05-7.01 (m, 1 H), 6.62-6.58 (m, 3 H), 5.82-5.72 (m, 1 H), 5.02-4.91 (m, 1 H), 4.43-4.38 (m, 1 H), 4.23-4.19 (m, 1 H), 3.55 (s, 3 H), 2.93-2.80 (m, 2 H), 2.51-1.97 (m, 2 H), 1.66-0.86 (m, 15H); ^{13}C NMR (d_6 -DMSO, 125 MHz), δ 171.9, 171.8, 171.1, 157.2, 138.6, 138.4, 129.1, 119.5, 115.8, 114.6, 113.5, 56.5, 53.5, 51.6, 36.5, 34.8, 32.8, 29.0, 28.0, 27.8, 25.8, 25.5, 24.8; HRMS, m/z 445.2683 (calcd for $\text{C}_{25}\text{H}_{36}\text{N}_2\text{O}_5$: 445.2702, error: 4 ppm).

Step B:


To the solution of **11a** (1.46 g, 3.28 mmol) in anhydrous THF (60 mL) under nitrogen at 0°C was added borane-THF solution (12 mL, 1.0 M, 12 mmol) cautiously. The resulting solution was stirred at 0°C under nitrogen for 1 h 40 min. Then ethanol (4 mL) and pH 7 buffer (8 mL) were added, followed by aqueous 30 % H_2O_2 solution (7.5 mL). After stirred at 0°C for 20 min, it was warmed to rt and stirred for 2 h. EtOAc (200 mL) and brine (100 mL) were added and layers were separated. Aqueous solution was extracted with EtOAc (2 X 150 mL). Combined organic solution was dried with magnesium sulfate, filtrated, concentrated *in vacuo*. Flash chromatography (2 to 5 % MeOH- CH_2Cl_2) afforded **11b** (1.05 g, 2.18 mmol, 68 %) as a white solid. ^1H NMR (400 MHz, d_6 -DMSO) δ 9.25 (s, 1 H), 8.30 (d, $J = 7.2$ Hz, 1 H), 7.68 (d, $J = 9.2$ Hz, 1 H), 7.05-7.01 (m, 1 H), 6.62-6.58 (m, 3 H), 4.43-4.18 (m, 3 H), 3.55 (s, 3 H), 3.37-3.33 (m, 2 H), 2.93-2.80 (m, 2 H), 2.20-2.03 (m, 2 H), 1.66-0.87 (m, 19H); ^{13}C NMR (d_6 -DMSO, 125 MHz), δ 172.1, 171.8, 171.2, 157.2, 138.4, 129.1, 119.5, 115.8, 113.5, 60.7, 56.5, 53.5, 51.7,

36.5, 35.1, 32.6, 32.4, 29.0, 28.5, 28.0, 25.8, 25.6, 25.4, 25.2; HRMS, m/z 463.2813 (calcd for $C_{25}H_{36}N_2O_5$: 463.2808, error: 1 ppm).


Step C:





To a solution of phenol alcohol **11b** (1.00 g, 2.16 mmol) and tri-*n*-butylphosphine (1.10 mL, 4.28 mmol) in anhydrous CH_2Cl_2 (100 mL) and THF (40 mL) at 0°C was added ADDP (1.08 g, 4.28 mmol). After stirring at 0°C for 1 h, the solution was warmed to rt and stirred for 3 h under nitrogen. TLC indicated complete consumption of the starting material. After removal of solvent *in vacuo*, the residue was partially purified by flash chromatography (0 to 3 % MeOH in CH_2Cl_2) to afford the macrocycle **11c** (650 mg, 1.46 mmol, 68 %). 1H NMR (400 MHz, d_6 -DMSO) δ 8.58 (d, J = 8.3 Hz, 1 H), 7.76 (d, J = 9.2 Hz, 1 H), 7.18-7.14 (m, 1 H), 6.76-6.65 (m, 3 H), 4.77-4.71 (m, 1 H), 4.32 (t, J = 8.5 Hz, 1 H), 3.97-3.93 (m, 1 H), 3.82-3.78 (m, 1 H), 3.67 (s, 3 H), 3.18-3.14 (m, 1 H), 2.98-2.92 (m, 2 H), 2.32-2.25 (m, 1 H), 2.02-2.01 (m, 1 H), 1.99-0.87 (m, 19H); ^{13}C NMR (d_6 -DMSO, 125 MHz), δ 172.1, 171.6, 171.4, 160.1, 158.8, 139.0, 129.1, 121.1, 113.0, 111.9, 66.4, 56.1, 52.0, 50.1, 40.6, 34.9, 34.2, 28.7, 28.3, 26.8, 26.3, 25.9, 25.5, 25.2, 24.2; HRMS, m/z 445.2685 (calcd for $C_{25}H_{36}N_2O_5$: 445.2702, error: 4 ppm).

Step D:

- 5 Aqueous lithium hydroxide solution (70 mg, 15 mL H₂O, 2.92 mmol) was added to a solution of methyl ester **11c** (330 mg, 0.742 mmol) in THF (20 mL) and ethanol (10 mL) at rt. The mixture was stirred at rt for 3 h. The progress of the reaction was monitored by TLC. After the solution was concentrated *in vacuo*, EtOAc (100 mL), 6 N HCl solution (10 mL) and water (50 mL) were added and the
- 10 layers were separated. The aqueous solution was extracted with EtOAc (2 X 80 mL). Organic solutions were combined, dried with magnesium sulfate, filtered and concentrated *in vacuo* to afford **11d** (260 mg, 0.604 mmol, 81 %) as a white solid.
- 15 ¹H NMR (400 MHz, d₆-DMSO) δ 8.43 (d, *J* = 8.3 Hz, 1 H), 7.73 (d, *J* = 9.3 Hz, 1 H), 7.17-7.13 (m, 1 H), 6.77-6.66 (m, 3 H), 4.67-4.62 (m, 1 H), 4.32-4.28 (m, 1 H), 3.98-3.93 (m, 1 H), 3.81-3.75 (m, 1 H), 3.17-3.13 (m, 1 H), 2.97-2.90 (m, 1 H), 2.32-2.26 (m, 1 H), 2.01-1.97 (m, 1 H), 1.67-0.85 (m, 19H); ¹³C NMR (d₆-DMSO, 125 MHz), δ 173.2, 171.6, 171.3, 158.8, 139.3, 129.0, 121.1, 113.1, 111.9, 66.4, 56.1, 50.8, 35.1, 34.3, 28.8, 28.3, 26.9, 26.3, 25.9, 25.6, 25.5, 25.2, 24.2; HRMS, *m/z* 431.2564 (calcd for C₂₅H₃₆N₂O₅: 431.2546, error: 4 ppm).

Step E:


- 5 To a solution of acid **11d** (0.140 g, 0.325 mmol), amine **B** (0.140 g, 0.325 mmol), HOObt (56 mg, 0.343 mmol) and EDCI (75 mg, 0.391 mmol) in anhydrous DMF (40 mL) and CH_2Cl_2 (20 mL) at -20°C was added NMM (0.107 mL, 0.973 mmol). After stirred at this temperature for 30 min, the reaction mixture was kept in a freezer for 18 h. Then EtOAc, brine and 5% H_3PO_4 were added. The
- 10 separated organic solution was washed, successively, with 5% H_3PO_4 , saturated aqueous sodium bicarbonate solution, water, and brine, dried with magnesium sulfate, filtered and concentrated *in vacuo*. Flash chromatography (2 to 5 % MeOH- CH_2Cl_2) afforded **11e** as a mixture of diastereomers (0.170 g, 0.211 mmol, 65%) as a white solid, which is used in the next reaction without further
- 15 purification.

Step F:

- 5 To the mixture of hydroxy amide **11e** (0.29 g, 0.36 mmol) and Dess-Martin reagent (0.45 g, 1.06 mmol) at rt was added anhydrous CH_2Cl_2 (60 mL), DMF (3 mL) and DMSO (3 mL). The resulting solution was vigorously stirred at rt for 2.5 h. More Dess-Martin reagent (300 mg, 0.71 mmol) was added and the reaction mixture was stirred for another hour. Saturated aqueous sodium bicarbonate and
- 10 sodium bisulfite solutions (40 mL each) were added and the mixture was vigorously stirred for 10 min before EtOAc (200 mL) and water (30 mL) were added and the layers were separated. The organic solution was washed with 5% H_3PO_4 solution (2 X 100 mL) and saturated NaHCO_3 solution (100 mL), dried with magnesium sulfate, filtered and concentrated *in vacuo*. Flash
- 15 chromatography (1 to 5 % MeOH- CH_2Cl_2) afforded **11** (100 mg, 0.124 mmol, 35%) as a white solid. ^1H NMR (400 MHz, d_6 -DMSO) δ 8.79-8.69 (m, 2 H), 8.36-8.16 (m, 2 H), 7.72-7.68 (m, 1 H), 7.42-7.33 (m, 5 H), 7.17-7.13 (m, 1 H), 6.77-6.63 (m, 3 H), 5.30-5.27 (m, 1 H), 5.09-5.04 (m, 1 H), 4.85-4.76 (m, 1 H), 4.29-



4.25 (m, 1 H), 3.98-3.74 (m, 1 H), 3.02-2.85 (m, 2 H), 2.32-2.27 (m, 1 H), 2.04-
1.96 (m, 1 H), 1.72-0.81 (m, 35 H); ^{13}C NMR ($\text{d}_6\text{-DMSO}$, 125 MHz), δ 196.5,
196.2, 171.65, 171.61, 171.5, 171.14, 171.07, 169.4, 167.6, 160.7, 158.84,
158.79, 139.5, 139.3, 136.6, 136.5, 128.92, 128.90, 128.7, 128.6, 128.1, 127.7,
5 127.4, 124.9, 121.34, 121.28, 113.1, 112.9, 112.0, 111.9, 81.3, 66.34, 66.30,
56.92, 56.87, 56.3, 56.2, 53.4, 53.3, 51.5, 50.9, 41.5, 41.4, 40.8, 40.7, 36.6, 36.1,
34.4, 34.3, 31.8, 31.6, 30.4, 29.1, 28.9, 28.4, 28.3, 27.5, 26.8, 26.21, 26.17, 25.9,
25.59, 25.55, 25.0, 24.2, 18.74, 18.66, 13.5, 13.4 ; HRMS, m/z 804.4542 (calcd
for $\text{C}_{25}\text{H}_{36}\text{N}_2\text{O}_5$: 804.4548, error: 1 ppm).

10 **Example 12: Preparation of Compound of Formula 12:**



12


100

Step A:**11****12**

A solution of the *t*-Butyl ester **11** (56.8 mg, 0.0706 mmol) in trifluoroacetic acid (15 mL) and CH₂Cl₂ (15 mL) was stirred at rt for 4 h. After the volatiles were removed *in vacuo*, the residue was dissolved in 50% MeOH-CH₂Cl₂ (3 mL), and concentrated to dryness *in vacuo* to afford an off-white solid **12** (50 mg, 0.0669 mmol, 95%). ¹H NMR (400 MHz, d₆-DMSO) δ 8.75-8.71 (m, 2 H), 8.36-8.16 (m, 2 H), 7.72-7.69 (m, 1 H), 7.39-7.31 (m, 5 H), 7.17-7.13 (m, 1 H), 6.76-6.63 (m, 3 H), 5.37-5.35 (m, 1 H), 5.07-5.04 (m, 1 H), 4.85-4.76 (m, 1 H), 4.29-4.25 (m, 1 H), 3.97-3.74 (m, 4 H), 3.02-2.86 (m, 2 H), 2.32-2.26 (m, 1 H), 2.01-1.97 (m, 1 H), 1.70-0.82 (m, 26 H); ¹³C NMR (d₆-DMSO, 125 MHz), δ 196.5, 196.2, 171.63, 171.59, 171.52, 171.48, 171.1, 171.06, 167.4, 160.6, 158.82, 158.78, 153.4, 139.4, 137.1, 137.01, 128.91, 128.88, 128.7, 128.65, 128.61, 128.5, 128.43, 128.39, 128.33, 128.32, 128.14, 128.12, 128.0, 127.7, 128.7, 127.63, 127.59, 127.5, 127.4, 126.8, 121.3, 115.9, 113.1, 112.9, 112.8, 112.0, 111.9, 111.88, 66.33, 66.29, 56.3, 56.2, 56.17, 53.34, 53.31, 53.27, 51.1, 50.9, 41.5, 40.84, 40.77, 40.7, 40.6, 40.56, 40.53, 40.5, 38.7, 38.6, 38.56, 38.53, 36.6, 36.1, 34.4, 34.3, 31.8,


31.6, 29.4, 29.1, 29.0, ϵ 28.9, 28.4, 28.3, 28.2, 26.9, 26.8, 26.79, 26.20, 26.16, 25.88, 25.86, 25.79, 25.75, 25.71, 25.66, 25.57, 25.54, 25.4, 25.0, 24.2, 18.7, 18.6, 13.5, 13.4; HRMS, m/z 748.3947 (calcd for $C_{25}H_{36}N_2O_5$: 748.3922, error: 3 ppm).

5 **Example 13: Preparation of Compound of Formula 13:**



13


Step A:




1g

13a


The desired compound **13a** was prepared according to the method of Example 11, Step A, except substituting 6-hydroxyhexanoic acid for 6-heptenoic acid (39%).

Step B:

5 The desired compound **13b** was prepared from **13a** according to the method of Example 11, Step C in 74% yield.



Step C:

10 The desired macrocyclic acid **13c** was prepared from its corresponding methyl ester **13b** according to the method of Example 11, Step D in 88 % yield as a white solid.


Step D:

- 5 The desired compound **13d** was prepared from **13c** and **B** according to the method of Example 11, Step E in 48% yield.


104

Step E:


- 5 The desired compound **13** was prepared from **13d** according to the method of Example 11, Step F in 70% yield.

Example 14: Preparation of Compound of Formula 14:

105


Step A:

13




14

The desired compound **14** was prepared from **13** according to the method of Example 12, Step A in quantitative yield.

5 Example 15: Preparation of Compound of Formula 15:

15


Step A:

15a

15b


A solution of 3-iodo-phenylalanine **15a**, (2.50 g, 8.59 mmol) and concentrated hydrochloric acid (2 mL, 24 mmol) in methanol was heated to reflux for 18 h. Removal of solvents *in vacuo* afforded a white solid **15b**, which was used in Step B without further purification.

5 **Step B:**




The desired compound **15c** was prepared in 84% yield from **15b** according to the method of Example 11, Step A. It was used in the next reaction without further purification.


10 **Step C:**



The desired compound **15d** was prepared from **15c** according to the method of Example 11, Step A (quantitative). It was used in the next reaction without further purification.

Step D:


The desired compound **15e** was prepared in 68% yield from **15d** according to the method of Example 11, Step A. It was used in the next reaction without further purification.

Step E:

A solution of **15e** (1.16 g, 2.04 mmol), triethylamine (2.90 mL, 20.6 mmol) in anhydrous acetonitrile (25 mL) and DMF (20 mL) in a thick walled tube was bubbled with Argon for 5 min. To this solution at rt was quickly added tetrakis(triphenylphosphine) palladium (0) (235 mg, 0.203 mmol). The tube was sealed with Teflon screw cap and heated to 85-90°C in an oil bath. After stirring for 3 h, it was cooled to rt, opened cautiously and poured onto EtOAc (100 mL). The solution was washed with 5% H₃PO₄ (4 X 50 mL) and water (50 mL). Organic layer was dried with magnesium sulfate, filtrated, concentrated *in vacuo*.


Flash chromatography (1 to 4 % MeOH-CH₂Cl₂) afforded the macrocycle **15f** (330 mg, 0.749 mmol, 37 %).

Step F:



5 The desired compound **15g** was prepared quantitatively from **15f** according to the method of Example 11, Step D. It was used in the next reaction without further purification.



Step G:



The desired compound **15h** was prepared in 77 % yield from **15g** according to the method of Example 11, Step F. It was used in the next reaction without further purification.

Step H:


5





The desired compound **15** was prepared in 55 % yield from **15h** according to the method of Example 1, Step H.

Example 16: Preparation of Compound of Formula 16:

10





110

Step A:


The desired compound **16** was prepared quantitatively from **15** according to the method of Example 12, Step A.

5 **Example 17: Preparation of Compound of Formula 17:**




Step A:

5 To the solution of **15f** (150 mg, 0.340 mmol) in EtOH (10 mL) and EtOAc (5 mL) was added 10 % palladium on carbon (20 mg). The suspension was stirred under hydrogen for 8 h during which the reaction progress was monitored by TLC. After filtration through a celite pad, solvents were removed *in vacuo* to afford the product as a white solid **17a** (150 mg, 0.339 mmol, quantitative). It was used in
10 the next reaction without further purification.



Step B:

The desired compound **17b** was prepared from **17a** according to the
15 method of Example 11, Step D. It was used in the next reaction without further purification.

Step C:


The desired compound 17c was prepared in 73 % yield (Steps B and C) from 17b according to the method of Example 11, Step E. It was used in the next reaction without further purification.

113



Step D:

The desired compound **17** was prepared in 46 % yield from **17c** according to the method of Example 11, Step F.

5 **Example 18: Preparation of Compound of Formula 18:**




114


Step A:

The desired compound **18** was prepared quantitatively from **17** according to the method of Example 12, Step A.


5 **Example 19: Preparation of Compound of Formula 19:**




1:15

Step A:


The desired compound **19b** was prepared in 64 % yield from **1g** and **19a** according to the method of Example 11, Step C.

5 Step B:

The desired compound **19c** was prepared from **19b** according to the method of Example 1, Step C. It was used in the next reaction without further purification.


Step C:

To a suspension of di-amine salt **19c** (75 mg, 1.52 mmol) and carbonyl diimidazole (260 mg, 1.60 mmol) in acetonitrile (400 mL) at rt was added triethylamine (0.26 mL, 1.85 mmol). The mixture was stirred for 3 days. Solvent was removed *in vacuo*. The residue dissolved in EtOAc/THF (100/50 mL) and the solution was washed with 5% H_3PO_4 , dried with magnesium sulfate, filtered, concentrated *in vacuo*. Flash chromatography (2 to 10 % MeOH- CH_2Cl_2) afforded **19d** (290 mg, 0.651 mmol, 43 %) as a white solid.


Step D:

The desired compound **19e** was prepared in 97 % yield from **19d** according to the method of Example 11, Step D. It was used in the next reaction without further purification.

117

Step E:


The desired compound **19f** was prepared in 66 % yield from **19e** and **B** according to the method of Example 11, Step E.

Step F:

118



The desired compound **19** was prepared in 66 % yield from **19f** according to the method of Example 11, Step E. Two products were partially separated by flash chromatography (0 to 5 % MeOH-CH₂Cl₂).

Example 20: Preparation of Compound of Formula 20:

**20**


5

Step A:

**19****20**

The desired compound **20** was prepared from **19** according to the method of Example 12, Step A.

Example 21: Preparation of Compound of Formula 21:



Step A:




5

10

A solution of 5-hexene-1-ol **21a** (10g, 50 mmol) in diethylether (100 mL) was treated with triethylamine (10.1g, 100 mmol, 2.0 equiv) and cooled to 0° C. A solution of phosgene in benzene (20%, 100 mL, 20g, 200 mmol, 4.0 equiv.) was added dropwise and the reaction mixture was stirred at rt for 12h. The triethylamine hydrochloride separating out was filtered and the filtrate was concentrated *in vacuo*. The residue **21b** was used directly for further studies without purification.

Step B:




15

A solution of **1f** (8.0g, 18.43 mmol) in CH₂Cl₂ (100 mL) was treated with triethylamine (2.43 g, 24.0 mmol, 1.3 equiv). The reaction mixture was cooled to -78° C and allylchloroformate (2.9g, 24 mmol, 1.3 equiv.) was added dropwise. The

reaction mixture was stirred at rt for 12 h and the reaction mixture was diluted with H₂O (100 mL) and aq. HCl (2M, 200 mL). The aq. layer was extracted with EtOAc (3x200 mL). The combined EtOAc layer were extracted with brine, dried (Na₂SO₄), filtered concentrate *in vacuo* and the residue **21c** was directly used for

5 Boc deprotection. ¹H NMR (CHCl₃, 300 MHz, δ , ppm) 7.29 (t, 1 H, J = 6.0 Hz), 7.06-6.98 (m, 3 H), 6.41 (d, 1 H, J =5.4 Hz), 6.05-5.95 (m, 1H), 5.42 (dd, 1H, J =1.2, 13.2), 5.31 (dd, 1 H, J =1.2, 13.2), 5.10 (d, 1 H, J =6.6 Hz), 4.91-4.87 (q, 1 H), 4.74 (d, 1H, J =4.5 Hz), 3.95-3.92 (m, 1 H), 3.70 (s, 3 H), 3.12 (d, 1 H J =4.2 Hz), 1.81-1.51 (m, 6H), 1.43 (s, 9 H), 1.21-0.91 (m, 6 H).

10 **Step C:**




A solution of **21c** (1.5 g) in HCl (4M in dioxane, 100 mL) was stirred at rt for 3 h. The disappearance of the starting material was followed by TLC and once the starting material disappeared the reaction mixture was concentrated *in vacuo* and the residue **21d** was dried in pump. It was used for coupling without further purification.

15


121

Step D:




A solution of the aminehydrochloride **21d** (4.0g, 8.9 mmol) in CH_2Cl_2 (50 mL) was treated with triethylamine (2.73 g, 27 mmol, 3.0 equiv, 3.8 mL) and cooled to -78°C . A solution of chloroformate **21b** (2.3g, 13.3 mmol, 1.5 equiv) in CH_2Cl_2 (30 mL) was added dropwise. The reaction mixture was stirred overnight at rt and diluted with aq. HCl (1M, 150 mL). The aqueous layer was extracted with EtOAc (3x100 mL). The combined ethyl acetate layers were extracted with H_2O (100 mL), brine (100 mL), dried (Na_2SO_4) filtered concentrated *in vacuo* and the residue was purified by chromatography (SiO_2 , EtOAc/Hexanes 3:7) to yield **21e** as colorless solid (5g, 80%).

Step E :



A solution of alloc-protected compound **21e** (4.0 g, 7.2 mmol) in dry THF (60.0 mL) was treated with dimedione (2.01g, 14.4 mmol, 2.0 equiv.), Pd(PPh₃)₄ (830 mg, 0.71 mmol, 10 mol%) at 0 °C and stirred at rt for 1h. The reaction mixture was concentrated *in vacuo* and the residue was purified by chromatography (SiO₂, EtOAc/Hexanes, 3:7) to yield a deprotected alcohol **21f** as a colorless solid (2.7g, 79%) ¹H NMR (CDCl₃, 300 MHz, δ ppm) 7.44 (bs, 1 H), 7.09 (s, 1 H, *J*=6.0 Hz), 6.75-6.72 (m, 2 H), 6.58-6.48 (m, 2 H), 5.81-5.71 (m, 1 H), 5.55 (d, 1 H, *J*=7.2 Hz), 4.98 (ddd, 1 H, *J*=1.5, 1.2, 9 Hz), 4.92 (dd, 1H, *J*=4.5, 0.9 Hz), 4.88-4.83 (m, 1 H), 4.12-3.97 (m, 1 H), 3.71 (s, 3 H), 3.09-2.98 (m, 2 H), 2.08-2.03 (m, 2 H), 1.722-1.40 (m, 10 H), 1.24-0.94(m, 5 H); ¹³C NMR (100 MHz, δ) 171.6, 157.3, 156.6, 138.3, 136.6, 129.8, 123.5, 120.6, 117.0, 114.9, 114.6, 65.7, 60.1, 53.2, 52.5, 40.4, 37.1, 33.3, 29.6, 28.6, 28.3, 26.0, 25.9, 25.1; CHN: calcd for C₂₅H₃₆N₂O₆: C=65.20% H=7.88% N=6.08%; Found: C=64.90% H=7.98% N= 6.01%.


Step F:



A solution of alkene **21f** (650 mg, 1.4 mmol) in anhydrous THF (5.2 mL) was cooled to 0°C and treated with BH₃•THF (1M soln in THF, 4.2 mL, 4.2 mmol, 3.0 equiv.) The reaction mixture was stirred at rt for 2 h and EtOH (2.0 mL) was added carefully with the evolution of hydrogen gas. After the H₂ evolution was complete the reaction mixture was treated with pH 7 buffer and treated with aq. H₂O₂ (30%, 5.0 mL) at 0 °C. The ice bath was removed and the mixture was stirred at rt for 3-4 h. The reaction mixture was extracted with EtOAc (3x100 mL). The combined organic layers were extracted with H₂O, brine, dried (MgSO₄), filtered, concentrated *in vacuo* and the residue was purified by chromatography (SiO₂, EtOAc/Hexanes 3:7) to yield hydroborated product as a colorless solid **21g** (400 mg, 60%) [α]_D 86.4 (c 0.3 CHCl₃, 25 °C); ¹H NMR (CDCl₃, 400 MHz, δ) 7.26 (s, 1 H), 7.08 (t, 1 H, *J*=5.7 Hz), 6.83 (d, 1 H, *J*=6.0 Hz), 6.71 (dd, 1 H, *J*=1.2, 4.5 Hz), 6.57 (bs, 1 H), 6.54 (d, 1 H, *J*=5.7 Hz), 5.68 (d, 1 H, *J*=6.9 Hz), 4.85 (dq, 1 H, *J*=4.2, 1.8 Hz), 4.05-3.97 (m, 3 H), 3.69 (s, 3 H), 3.60 (t, 2 H, *J*=4.8 Hz), 3.08-2.97 (m, 2 H), 1.77-1.53 (m, 10H), 1.42 1.25 (m, 4 H), 1.24-0.92 (m, 5 H); ¹³C NMR (CDCl₃, 100 MHz, δ) 171.8, 171.8, 157.6, 156.9, 136.9, 130.0, 120.8, 117.0, 114.8, 65.7, 62.7, 60.3, 53.3, 52.7, 40.5, 37.4, 32.5, 29.7, 29.0, 28.8, 26.2, 26.0, 25.6, 25.4 MS (FAB, NBA/DMSO, *m/z*, relative intensity) 479 ([M+1]⁺, 100), 296 (40), 196 (25), 156 (25), 136 (25), 112 (20). HRMS calcd. for C₂₅H₃₉N₂O₇ (M+1)⁺: 479.2760; found 479.2757.


124

Step G:



A solution of PPh_3 (385 mg, 1.47 mmol, 1.75 equiv)) in CH_2Cl_2 (10 mL) was treated with the compound **21g** (400 mg, 0.84 mmol) and cooled to 0°C . A solution of DEAD (220 mg, 1.26 mmol, 1.5 equiv.) in CH_2Cl_2 (10 mL) was added dropwise and stirred at rt for 3 h. The reaction mixture was concentrated *in vacuo* and the residue was purified by chromatography (SiO_2 , EtOAc/Hexanes 1:9) to yield cyclic product **21h** as a colorless solid. (110 mg, 25%)


Step H:



A solution of cyclic carbamate **21h** (200mg, 0.44 mmol) in dioxane (30 mL), CH_3OH (20 mL) and CH_2Cl_2 (20 mL) was treated with $\text{LiOH}\cdot\text{H}_2\text{O}$ (80 mg, 2.0 mmol, 4.5 equiv) and stirred at rt for 4 h. The reaction was concentrated *in vacuo* and diluted with HCl (4M soln in dioxane, 10 mL). The water was removed by lyophilizer to yield the crystalline acid **21i** directly used for coupling.

125


Step I :




- A solution of the hydrolyzed acid **21i** (210 mg, 0.47 mmol) in dry DMF (5.0 mL) and CH_2Cl_2 (5.0 mL) was treated with HOObt (125 mg, 0.70 mmol, 1.5 equiv) and cooled to 0 °C and Hünigs base (258 mg, 2.0 mmol, 4.0 equiv, 369 μL) was added. To this mixture was added EDCI (134 mg, 0.70 mmol, 1.5 equiv) and the reaction mixture was stirred at 0° C for 0.5 h and treated with the amine hydrochloride **B** (253 mg, 0.58 mmol, 1.25 equiv.). The reaction mixture was stored in freezer for 24 h and concentrated *in vacuo* to remove DMF and CH_2Cl_2 .
- 10 The residue was diluted with aq. HCl (2M, 30 mL) and extracted with CH_2Cl_2 (3x50 mL) The combined organic layer was extracted with aq. HCl (2M, 30 mL), aq. NaOH (1M) brine (2x50 mL), dried (MgSO_4) and concentrated *in vacuo*. The residue **21j** (220 mg) was oxidized without further purification.

126

Step J:




A solution of alcohol **21j** (220 mg, 0.26 mmol) in CH_2Cl_2 (5.0 mL) was treated with Dess-Martin reagent (200 mg, 0.47 mmol, 1.8 equiv.). The reaction mixture was stirred at rt for 1 h and diluted with aq. NaHCO_3 (15 mL) and aq. $\text{Na}_2\text{S}_2\text{O}_3$ (15 mL). The reaction mixture was stirred at rt for 20 min and the reaction mixture was extracted with CH_2Cl_2 (3x30 mL). The combined organic layers were extracted with aq. Na_2CO_3 , dried (Na_2SO_4), filtered, concentrated *in vacuo* and the residue was purified by chromatography (SiO_2 , CH_3OH (2M NH_3)/ CH_2Cl_2 1:20) to yield ketoamide **21** (60 mg, 27%) of a colorless solid.

Example 22: Preparation of Compound of Formula 22:


127

Step A:



22


A solution of *tert*-butyl ester **21** (50 mg, 0.059 mmol) in dry CH₂Cl₂ (2.0 mL) was treated with TFA (2.0 mL) and stirred at rt. for 4 h. The reaction mixture was concentrated *in vacuo* and the residue was repeatedly dissolved in heptanes/CH₂Cl₂ and concentrated *in vacuo* several times to yield a fine tan solid **22** (47 mg), which was dried *in vacuo*.

Example 23: Preparation of Compound of Formula 23:


23

128


Step A:



A solution of acid **1d** (255mg, 1.0 mmol) in DMF (2.0 mL) was treated with HOBt (202 mg, 1.5 equiv) and Hünigs base (517 mg, 4.0 mmol, 4.0 equiv, 738 μ L). The reaction mixture was cooled to 0° C and treated with DCC (258 mg, 1.25 mmol, 1.25 equiv.) After stirring the mixture for 1h Histidine-OCH₃•2HCl **23a** (242.0 mg, 1.0 mmol) was added and stirred at rt overnight. The reaction mixture was concentrated *in vacuo* and extracted in EtOAc (3x50 mL) and aq. NaHCO₃ (50 mL). The combined organic layer was concentrated *in vacuo* and the residue was purified by chromatography (SiO₂, CH₃OH/CH₂Cl₂ 1:19) to yield dipeptide **23b** as a colorless solid (380 mg, 93%) ¹H NMR (d₆-DMSO, 400 MHz, δ , ppm) 8.17 (d, 1 H, *J*=7.2 Hz), 7.48 (s, 1 H), 6.77 (s, 1 H) 6.57 (bs, 1 H), 5.54 (d, 1H, *J*=7.6 Hz), 4.47 (q, 1 H, *J*=7.2 Hz), 3.79 (t, 1 H, *J*=8.4 Hz), 3.55 (s, 3 H), 3.36-3.20 (m, 2 H), 2.94-2.82 (m, 2 H), 1.70-1.47 (bm, 6H), 1.35 (s, 9 H), 1.46-0.85 (m, 5 H); ¹³C NMR (d₆-DMSO, 100 MHz, δ ppm) 172.5, 171.9, 157.3, 155.9, 135.4, 78.6, 59.5, 52.9, 52.3, 34.1, 29.6, 28.9, 28.6, 26.5, 26.3, 26.0, 25.2 FAB MS: (NBA-G/TG-DMSO, *m/z* relative intensity) 409. [(M+1)⁺, 100], 353. (10), 170 (20); HRMS calcd for C₂₀H₃₃N₄O₆: 409.2451; found 409.2466; CHN Calcd for C₂₀H₃₂N₄O₅: C=58.81% H=7.90%, N=13.72%; Found: C=58.70% H=7.78% N=13.43%.


Step B:

A solution of ω -bromoheptenoic acid (223 mg, 1.0 mmol) in DMF (3.0 mL) was treated with deprotected amine hydrochloride **23b** (380 mg, 1.0 mmol, 1.0 equiv) and Hünig's base (387 mg, 3.0 mmol, 3.0 equiv) was added. The reaction mixture was treated with PyBroP (465 mg, 1.0 mmol) and stirred at rt for 3 h. The reaction mixture was concentrated *in vacuo* and the residue was purified by chromatography (SiO_2 , $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$, 1:19) to yield a colorless solid (220 mg, 50 %). MS (FAB) 515.2 $[(\text{M}+1)^+]$, 100], 513.2 $[(\text{M}+1)^+]$, 95], 469 (60), 433 (20), 170 (40). HRMS calcd. for $\text{C}_{23}\text{H}_{38}\text{BrN}_4\text{O}_4$: 513.2076 found: 513.2073.

Step C:

A solution of bromo-compound **23c** (100 mg, 0.23 mmol), in 2-butanone (4.0 mL) was treated with Na_2CO_3 (31.0 mg, 0.29 mmol, 1.25 equiv) and with LiI (50 mg, 0.37 mmol 1.3 equiv.) and heated at reflux for 24 h. The reaction mixture was concentrated *in vacuo* and the residue was diluted with water. The residue was extracted with CH_2Cl_2 (3x30 mL). The combined organic layer was dried (Na_2SO_4) and purified by chromatography (SiO_2 , $\text{CH}_3\text{OH}:\text{CH}_2\text{Cl}_2$ 1:19) to yield the cyclized compound **23d** (25 mg, 31%); R_f : 0.68 (2M NH_3 in $\text{CH}_3\text{OH}:\text{CH}_2\text{Cl}_2$:


1:19) ^1H NMR (CDCl_3 , 400 MHz, δ , ppm) 8.17 (d, 1 H, $J=8.8$ Hz) 7.33 (s, 1 H), 6.48 (d, 1 H, $J=8.4$ Hz), 4.90-4.85 (m, 1H), 4.26 (t, 1 H, $J=8.0$ Hz), 3.82-3.74 (m, 2 H), 3.69 (s, 3H), 3.16- 3.11 (m, 2 H) 2.91-2.84 (m, 1 H), 2.30-2.01 (m, 2 H), 1.65-1.59 (m, 11 H), 1.18-0.96 (m, 11H): ^{13}C NMR (CDCl_3 , 100 MHz, δ ppm): 172.8, 172.4, 171.9, 138.2, 136.8, 57.6, 52.5, 51.7, 46.6, 41.6, 36.0, 30.9, 29.5, 28.8, 27.3, 26.7, 26.4, 26.3, 26.2, 25.2, 24.8 MS: (Electron spray, m/z relative intensity): 433.1 $[(M+1)^+]$, 100]; HRMS: Calcd. for $\text{C}_{23}\text{H}_{37}\text{N}_4\text{O}_4$ 433.2815 found 433.2822.

Step D:

A solution of methyl ester **23d** (200 mg, 0.46 mmol) in CH_3OH (5.0 mL) H_2O (0.5 mL) was treated with $\text{LiOH}\cdot\text{H}_2\text{O}$ (30 mg, 0.75 mmol, 1.6 equiv.) The reaction mixture was stirred at rt for 15 h and concentrated *in vacuo* and dried in pump to yield hydrolyzed compound **23e** which was used for coupling directly.


131

Step E:





A solution of the acid **23e** in CH_2Cl_2 (3.0 mL), DMF (5.0 mL) was treated with HOObt (115 mg, 0.70 mmol, 1.50 equiv) and EDCI (113 mg, 0.60 mmol, 1.25 equiv). The reaction mixture was then treated with Et_3N (190 mg, 1.88 mmol, 271 μL , 4.0 equiv) and amine hydrochloride **B** (201 mg, 0.5 mmol, 1.1 equiv.) The reaction mixture was stirred at rt for 13 h and diluted with H_2O . The aqueous layer was extracted with CH_2Cl_2 (3x50 mL) and the combined organic layers were extracted with aq. NaOH (1M, 50 mL) and dried (Na_2SO_4). The dried organic layer was filtered and concentrated *in vacuo* to yield a colorless residue **23f** (442 mg) which was dried *in vacuo* and directly used for further oxidation. MS: (Electron spray, m/z relative intensity): 794 $[(M+1)^+]$, 100].



Step F:



A solution of hydroxy-amide **23f** (50 mg, 0.064 mmol) in CH₂Cl₂ (3.0 mL) was treated with Dess Martin reagent (53 mg, 0.13 mmol, 2.0 equiv) and stirred at rt for 3 h. The reaction mixture was diluted with aq. satd. Na₂S₂O₃ (20 mL) and stirred at rt for 15 min. The aqueous layer was extracted with CH₂Cl₂ (3x30 mL). The organic layer was dried (Na₂SO₄) filtered concentrated *in vacuo* and purified by chromatography (SiO₂, CH₃OH/CH₂Cl₂, 1:15) to yield ketoamide **23** (20mg, 40%); MS (FAB, NBA-G/TG-DMSO, *m/z* relative intensity) 824 [(M+CH₃OH)⁺, 100], 792 [(M+1)⁺, 60], 447 (20); HRMS calcd for C₄₂H₆₂N₇O₈ (M+1)⁺: 792.4660: found 792.4659.

Example 24: Preparation of Compound of Formula 24:**Step A:**


A solution of *tert*-butyl ester **23** (17 mg, 21.5 μ mol) in dry CH_2Cl_2 (2.0 mL) was treated with TFA (2.0 mL) and stirred at rt. for 8 h. The disappearance of the ester to the base line was followed by TLC ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$, 1:19). The reaction mixture was concentrated *in vacuo* and the residue was repeatedly dissolved in $\text{CH}_3\text{OH}/\text{heptanes}/\text{CH}_2\text{Cl}_2$ and concentrated *in vacuo* several times to yield **24** as fine colorless solid (7 mg). MS: (Electron spray, *m/z* relative intensity): 768 $[(\text{M}+\text{CH}_3\text{OH})^+]$, 100], 736 $[(\text{M}+1)^+]$, 60], 46 (10).

Example 25: Preparation of Compound of Formula 25:**25****5 Step A:**

10 A solution of Boc-4-Chlorophenylalanine **25a** (523 mg, 1.75 mmol) in dichloroethane (37 mL) was treated with $\text{CpRu}(\text{CH}_3\text{CN})_3 \text{PF}_6$ **1b** (760 mg, 1.75 mmol, 1.0 equiv) and heated at reflux for 2 h. The reaction mixture was cooled to 0 °C and filtered. The filtrate was concentrated *in vacuo* and dissolved in minimum CH_3CN and treated with a large excess of Et_2O . The solid separating out was separated and dissolved in $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ (1:1, 50 mL) and concentrated *in vacuo* to obtain **25b** as a brown foam (640 mg, 69%).

135


Step B:



A solution of carboxylic acid **25b** (2.4 g, 3.80 mmol) in dry DMF (15 mL) was treated with Hünigs base (1.64 g, 12.64 mmol, 4.0 equiv, 2.9 mL) and HOBT (661 mg, 4.38 mmol, 1.5 equiv). The reaction mixture was cooled to 0° C and the treated with EDCI (699 mg, 3.95 mmol, 1.25 equiv) and stirred for 15 min. To this reaction mixture was added amine hydrochloride **1g** (1.50 g, 4.00 mmol, 1.2 equiv) and the reaction mixture was stirred at rt for 12 h. The DMF was distilled out and the residue was diluted with water (30 mL) and the aqueous layer was extracted with CH₂Cl₂ (3x50 mL). The combined organic layers were extracted with aq NaHCO₃ (30 mL), aq. HCl (30 mL), brine, dried (Na₂SO₄) filtered concentrated *in vacuo* and the crude product **25c** (2.5 g, 69%) was used for further cyclization without purification.

Step C:


136



A solution of compound **25c** (100 mg 0.11 mmol) in dry DMF (10 mL) was degassed with dry N_2 and treated with Cs_2CO_3 (170 mg, 0.5 mmol, 5.0 equiv) and stirred at rt. for 12 h. The solvent DMF was distilled off and the residue was diluted with water (35 mL) and extracted with CH_2Cl_2 (3x100 mL). The combined organic layers were dried (Na_2SO_4) filtered, concentrated *in vacuo* and dried in vacuum overnight. It was used for photolytic removal of Ru without further purification.

The cyclized compound from the previous step was dissolved in CH_3CN and photolysed in a Raynot ($\lambda=350$ nm) for 48h. The reaction mixture was concentrated *in vacuo* and the residue was purified by chromatography (SiO_2 , EtOAc/Hexanes 2:1) to yield **25d** as a tan colored solid (29 mg, 46 %). MS (FAB, NBA-G/TG-DMSO, *m/z* relative intensity), 580 [$(M+1)^+$, 80], 524 (100), 418 (40), 462 (30), 452 (20), 313 (60), 253 (20).

Step D:




A solution of ester **25d** (150 mg, 0.26 mmol) in THF (3 mL), CH_3OH (3.0 mL) and H_2O (3.0 mL) was treated with $LiOH \cdot H_2O$ (18 mg, 0.43 mmol, 1.65

equiv.) and stirred at rt for 35 min. The reaction mixture was acidified with conc HCl (13 M, 1mL) and extracted in CH₂Cl₂ (3x50 mL). The combined organic layers were dried (Na₂SO₄) filtered and concentrated *in vacuo* to yield acid **25e** which was used directly for the coupling without further purification.





A solution of acid **25e** (150 mg, 0.27 mmol) in dry CH₂Cl₂ (2.0 mL), was
5 treated with HOBt (62 mg, 0.40 mmol) and Hünigs base (139 mg, 1.1 mmol, 4.0
equiv.) The reaction mixture was cooled to 0° C and treated with EDCI (53 mg,
0.34 mmol, 1.25 equiv) and stirred for 30 min. The reaction mixture was treated
with amine F (88 mg, 0.29 mmol, 1.22 equiv.) and stored in the freezer for 12 h.
The reaction mixture was concentrated *in vacuo* and diluted with H₂O (50 mL).
10 The aqueous layer were extracted with CH₂Cl₂ (3x50 mL). The combined organic
layers were extracted with aq. HCl (1M, 3x20 mL) aq. NaOH (1M, 3x20 mL), dried
(Na₂SO₄) filtered concentrated *in vacuo* to obtain a colorless solid **25f** (138 mg)
which was used for oxidation.



Step F:



A solution of alcohol **25f** (140 mg, 0.143 mmol) in CH₂Cl₂:THF (1:1, 5.0 mL) was treated with Dess-Martin reagent (121 mg, 0.42 mmol, 3.0 equiv.) The reaction mixture was stirred at rt for 2 h and the mixture was concentrated *in vacuo*. The residue was purified by chromatography (SiO₂, CH₃OH/CH₂Cl₂ 1:32) to yield oxidized product **25** (57mg, 41%) as a colorless solid.

Example 26: Preparation of Compound of Formula 26:**Step A:**


A solution of the benzyl ester **25** (30 mg, 38.0 μmol) in $\text{CH}_3\text{OH}/\text{THF}$ (1:1, 4.0 mL) was treated with Pd/C (20 mg, 10%) and H_2 was bubbled through it. A drop of acetic acid was added to accelerate the reduction. The reaction mixture was filtered through a plug of celite and the filtrate was concentrated *in vacuo*. The residue **26** was analyzed without further purification.

Example 27: Preparation of Compound of Formula 27:**Step A:**



A solution of acid **25e** (100 mg, 0.17 mmol) in dry CH_2Cl_2 was treated with HOObt (41 mg, 0.26 mmol) and Hünigs base (91 mg, 0.70 mmol, 4.0 equiv.) The reaction mixture was cooled to 0°C and treated with EDCI (35 mg, 0.22 mmol, 1.25 equiv) and stirred for 30 min. The reaction mixture was treated with amine **D** (71 mg, 0.22 mmol, 1.22 equiv.) and stored in the freezer for 12 h. The reaction mixture was concentrated *in vacuo* and diluted with H_2O (30 mL). The aqueous layers was extracted with CH_2Cl_2 (3x30 mL). The organic layers were extracted with aq. HCl (1M, 30 mL) aq. Na_2CO_3 (1M, 30 mL), dried (Na_2SO_4) filtered

concentrated *in vacuo* to obtain **27a** colorless solid (119 mg) which was used for oxidation. MS (FAB), 842 [(M+1), 100], 765 (20), 735 (10), 657 (20), 575 (10), 492 (10), 464 (20), 446 (30). HRMS calcd. for C₄₆H₆₀N₅O₁₀ (M+1)⁺: 842.4339; found 842.4336.



Step B:



A solution of alcohol **27a** (120 mg, 0.143 mmol) in CH₂Cl₂:THF (1:1, 3.0 mL) was treated with Dess-Martin reagent (180 mg, 0.42 mmol, 3.0 equiv.) The reaction mixture was stirred at rt. for 2 h and the mixture was concentrated *in vacuo*. The residue was purified by chromatography (SiO₂, CH₃OH/CH₂Cl₂ 1:32) to yield oxidized product **27** as a colorless solid. MS (FAB, NBA-G/TG-DMSO, *m/z rel int*), 840 [(M+1)⁺, 50]. HRMS calcd. for C₄₆H₅₈N₅O₁₀ (M+1)⁺: 840.4184; found 840.4199.


Example 28: Preparation of Compound of Formula 28:**Step A:**

A solution of benzyl ester 27 (40 mg, 47.0 μ mol) in CH₃OH/THF (1:1, 6.0 mL) was treated with Pd/C (30 mg, 10%) and H₂ was bubbled through it. A drop of acetic acid was added to accelerate the reduction. The reaction mixture was filtered through a plug of celite and the filtrate was concentrated *in vacuo* to yield 28.

Example 29: Preparation of Compound of Formula 29:**Step A:**


A solution of 4-chlorophenylalanine **29a** (1.5g, 7.5 mmol) in THF (20 mL) and H₂O (20 mL) was treated with NaOH (900 mg, 22.5 mmol, 3.0 equiv.) and cooled to 0°C. A solution of acetyl chloride (707 mg, 9.00 mmol, 1.25 mmol) in THF (10 mL) was added dropwise and the reaction mixture was stirred overnight at rt. The reaction mixture was acidified with aq. HCl (1M, 10 mL) and extracted with CH₂Cl₂ (3x30 mL). The combined organic layers were dried (Na₂SO₄) filtered concentrated *in vacuo* to yield **29b** which was used in the next step without purification.

Step B:




A solution of N-acetyl-4-chlorophenylalanine **29b** (1.39 g, 5.75 mmol) in dichloroethane (118 mL) was treated with CpRu(CH₃CN)₃ PF₆ **1b** (2.5 g, 5.8 mmol, 1.0 equiv.) and heated at reflux for 2 h. The reaction mixture was cooled to 0 °C and filtered. The filtrate was concentrated *in vacuo* and dissolved in CH₃CN (15 mL) and treated with Et₂O (150 mL). The gum separating out was separated by decanting the ether and the residue was dissolved in CH₂Cl₂/CH₃OH (1:1, 50 mL) and concentrated *in vacuo* to obtain **29c** as a brown foam (2.2 g, 69%). MS: (Electron spray, *m/z rel int*): 408 [(M-PF₆)⁺, 100].

Step C:



A solution of carboxylic acid **29c** (2.0 g, 4.00 mmol) in dry DMF (20 mL) was treated with Hünig's base (2.06 g, 16.0 mmol, 4.0 equiv., 2.9 mL) and HOBt (810 mg, 6.0 mmol, 1.5 equiv.). The reaction mixture was cooled to 0°C and then treated with EDCI (888 mg, 5.0 mmol, 1.25 equiv.) and stirred for 0.5 h. To this reaction mixture was added amine hydrochloride **1g** (1.48 g, 7.14 mmol, 1.2 equiv.) and the reaction mixture was stirred at rt. for 12 h. The DMF was distilled out and the residue was diluted with water and the aqueous layer was extracted with CH_2Cl_2 (3x100 mL). The combined organic layers were extracted with aq. NaHCO_3 (200 mL), aq. HCl (100 mL), brine, dried (Na_2SO_4) filtered concentrated *in vacuo* and the crude product **29d** (1.2 g, 38%) was used for cyclization without further purification.


Step D:



A solution of chloro-compound **29d** (1.2 g 1.5 mmol) in dry DMF (120 mL) was degassed with dry N₂, treated with Cs₂CO₃ (2.4 g, 7.4 mmol, 5.0 equiv.) and stirred at rt. for 23 h. The solvent DMF was distilled off and the residue was diluted with water (300 mL) and extracted with propionitrile (3x100 mL). The combined organic layers were dried (Na₂SO₄) filtered, concentrated *in vacuo* and dried in vacuum overnight. It was used for photolytic removal of Ru without further purification.


The cyclized compound from the previous step was dissolved in CH₃CN (40 mL) and photolyzed in a Raynot ($\lambda=350$ nm) for 48h. The reaction mixture was concentrated *in vacuo* and the residue was purified by chromatography (SiO₂, EtOAc/Hexanes 4:1) to yield a tan colored solid **29e** (240mg, 38 %). MS (FAB, NBA-G/TG-DMSO, *m/z* relative intensity), 522[(M+1)⁺, 100].

Step E:




A solution of ester **29e** (200 mg, 0.42 mmol) in CH₃OH (5 mL), CH₂Cl₂ (13 mL) and H₂O (2.0 mL) was treated with LiOH·H₂O (41 mg, 1.0 mmol, 2.4 equiv.) and stirred at rt. for 3 h. The reaction mixture was acidified with aq. HCl (13 M, 1 mL) and extracted in CH₂Cl₂ (3x50 mL) and EtOAc (3x50 mL). The combined organic layers were dried (Na₂SO₄) filtered and concentrated *in vacuo* to yield acid **29f** (178 mg) which was used directly for the coupling without further purification.


Step F:




A solution of acid **29f** (90 mg, 0.18 mmol) in dry DMF (1.0 mL) was treated with HOBT (45 mg, 0.33 mmol, 1.6 equiv.), Hünigs base (142 mg, 1.1 mmol, 5.0 equiv.) and amine **B** (118 mg, 0.28 mmol, 1.47 equiv.) The reaction mixture was cooled to 0° C and treated with EDCI (63 mg, 0.33 mmol, 1.6 equiv.) and stirred at 0 °C for 20 min. for 12 h. The reaction mixture was concentrated *in vacuo* and diluted with H₂O (30 mL). The combined aqueous layers were extracted with CH₂Cl₂ (3x30 mL) and EtOAc (3x30 mL). The organic layers were extracted with aq. NaOH (2M, 30 mL), dried (Na₂SO₄) filtered concentrated *in vacuo* to obtain a colorless solid **29g** (50 mg, 32%) which was used for oxidation. MS: (Electron spray, *m/z rel int*): 883 [(M+1)⁺, 100], 522 (30), 394 (60).



Step G:

A suspension of alcohol **29g** (50 mg, 60.0 μ mol) in CH_2Cl_2 (2.0 mL) was treated with Dess-Martin reagent (40 mg, 0.94 mmol, 2.0 equiv.) The reaction mixture was stirred at rt. for 3h and the mixture was concentrated *in vacuo*. The residue was purified by chromatography (SiO_2 , $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$: 1:32) to yield oxidized product **29** (41 mg, 80%) as a colorless solid. MS: (FAB, m/z , *rel. int.*) 881 $[(M+1)^+$, 100), 825 (170), 248 (100).

Example 30: Preparation of Compound of Formula 30:




A solution of *tert*-butyl ester **29** (23.0 mg, 26.0 μ mol) was treated with TFA/CH₂Cl₂ (1:1, 2.0 mL) and stirred at rt. for 4 h. The disappearance of the ester to the base line was followed by TLC (CH₃OH/CH₂Cl₂ 1:24). After the deprotection was complete the reaction mixture was concentrated *in vacuo* and the residue was repeatedly treated with heptanes/CH₂Cl₂ (4.0 mL) and concentrated to yield a tan solid **30** (13.0 mg, 100%). MS: (Electron spray, *m/z rel int*): 825 [(M+1)⁺, 100].

Example 31: Preparation of Compound of Formula 31:**31****Step A:**



A solution of acid **29f** (150 mg, 0.29 mmol) in dry DMF (4.0 mL), CH₂Cl₂ (3.0 mL) was treated with HOBt (58 mg, 0.44 mmol) and Hünigs base (149 mg, 1.1 mmol, 4.0 equiv.) The reaction mixture was cooled to 0° C and treated with EDCI (82 mg, 0.44 mmol, 1.5 equiv.) and stirred for 30 min. The reaction mixture was treated with amine **E** (88 mg, 0.29 mmol, 1.22 equiv.) and stirred at rt. for 12 h. The reaction mixture was concentrated *in vacuo* and diluted with H₂O (30 mL). The aqueous layer was extracted with CH₂Cl₂ (3x30 mL). The combined organic layers were extracted with aq. HCl (1M, 3x20 mL), aq. NaOH (1M, 3x20 mL), dried (Na₂SO₄) filtered concentrated *in vacuo* to obtain a colorless solid **31a** (56

mg) which was used for oxidation. MS: (Electron spray, *m/z rel int*): 750 [(M+1)⁺, 20], 663 (10), 522 (10), 416 (20), 247 (30).



Step B:



A solution of alcohol **31a** (56 mg, 75 μ mol) in CH₂Cl₂ (5.0 mL) was treated with Dess-Martin reagent (93 mg, 0.22 mmol, 3.0 equiv.) The reaction mixture was stirred at rt. for 4 h and the mixture was concentrated *in vacuo*. The residue was purified by chromatography (SiO₂, CH₃OH/CH₂Cl₂: 1:19) to yield oxidized product **31** (34 mg, 60 %) as a colorless solid. MS: (Electron spray; *m/z rel int*): 748 [(M+1)⁺, 35], 692 (5), 279 (100).


Example 32: Preparation of Compound of Formula 32:**Step A:**

A solution of *tert*-butyl ester **31** was treated with TFA/CH₂Cl₂ (1:1, 4.0 mL) and stirred at rt. for 4 h. The disappearance of the ester to the base line was followed by TLC (CH₃OH/CH₂Cl₂ 1:24). After the deprotection was complete the reaction mixture was concentrated *in vacuo* and the residue was repeatedly treated with heptanes/CH₂Cl₂ (4.0 mL) and concentrated to yield **32** as a tan solid.

Example 33: Preparation of Compound of Formula 33:**Step A:**


A solution of acid **33a** (4.5g, 25.0 mmol) in dioxane (30 mL) and benzene (80 mL) was treated with BnOH (8.0 g, 74 mmol, 3.0 equiv.) and TsOH.H₂O (713 mg, 3.75 mmol, 10 mol%). The reaction mixture was heated at reflux for 5 h, when the water was separated using a Dean-Stark apparatus. The reaction mixture was concentrated *in vacuo* and the residue was purified by chromatography (SiO₂, EtOAc/Hexanes 3:7) to yield benzyl ester **33b** as a colorless oil (4.2 g, 62%); *R_f* : 0.22 (EtOAc/Hexanes 3:7); ¹³C NMR (CH₃OD, 75 MHz, δ): 175.1, 158.2, 139.7, 130.3, 129.5, 129.3, 121.7, 117.4, 114.6, 73.1, 67.6, 41.6; MS (FAB, G/TG-DMSO, *m/z*, relative intensity): 351 ([M+DMSO]⁺, 70), 273 ([M+1]⁺, 100), 255 (20), 227 (30), 181 (40); HRMS: Calcd. for C₁₆H₁₇O₄ (M+1)⁺ 272.1049; found 272.1054.

Step B:




A solution of benzyl ester **33b** (3.8 g, 12.9 mmol) in CH_2Cl_2 (100 mL) was treated with Et_3N (1.55 g, 15.4 mmol, 2.2 mL, 1.1 equiv.), cooled to -78°C (2-PrOH, dry ice) and a solution of allyl chloroformate (1.84 g, 15.36 mmol, 1.1 equiv.) in CH_2Cl_2 (10 mL) was added dropwise. The reaction mixture was allowed to warm up to the rt. and diluted with aq. HCl (1M, 100 mL). The reaction mixture was extracted with EtOAc (3x100 mL). The combined organic layer was washed with aq. HCl (100 mL, 1M), brine (100 mL), dried (MgSO_4) concentrated *in vacuo* to yield **33c** which was used in the next step without further purification. R_f : 0.43 (EtOAc/Hex 7:13); ^{13}C NMR (CH_3OD , 75 MHz, δ) 174.8, 162.5, 155.0, 152.5, 140.3, 137.1, 132.8, 130.3, 129.6, 129.5, 129.4, 123.2, 120.3, 119.4, 72.7, 70.1, 67.7, 41.2, 29.9.

Step C:



A solution of Boc-cyclohexylglycine monohydrate **1d** (6.02 g, 23.4 mmol, 2.0 equiv.) was dissolved in CH_2Cl_2 and dried (MgSO_4). The mixture was filtered


and the residue was further azeotropically dried with toluene. The residue was dissolved in CH_2Cl_2 , and treated with HOBt (4.73 g, 35.1 mmol, 2.9 equiv.) EDCI (6.7 g, 35.1 mmol, 2.9 equiv.) and Hünigs base (8.31 g, 64.3 mmol, 11 mL) It was stirred at rt. for 30 min. and the alloc protected alcohol **33c** (4.3 g, 12.04 mmol) was added. The reaction mixture was stirred at rt. for 36 h and diluted with aq. HCl (1M, 100 mL) and extracted with EtOAc (3x100 mL). The combined organic layers were extracted with aq. NaOH (1M, 100 mL), brine (100 mL), dried, concentrated *in vacuo* and purified by chromatography (SiO_2 , EtOAc/Hex 1:4) to yield depsipeptide **33d** (7.1g 100%). R_f : 0.18 (EtOAc/Hex 1:4); HRMS: Calcd. for $\text{C}_{28}\text{H}_{34}\text{O}_7$ (M-Boc) $^+$ 496.2335 : found 496.2333.

Step D:

A solution of alloc-protected depsipeptide **33d** (7.8 g, 13.0 mmol) in dry THF (200 mL) was treated under N_2 with dimedione (3.27 g, 23.4 mmol, 2.0 equiv.) and $\text{Pd}(\text{Ph}_3\text{P})_4$ (780 mg, 0.67 mmol, 5 mol%). The reaction mixture was stirred at rt. for 1h and the disappearance of reactant was followed by TLC (EtOAc/Hex 1:4). The reaction mixture was concentrated *in vacuo* and the residue was purified by chromatography (SiO_2 , EtOAc/Hexanes 1:4) to yield phenol **33e** (5.2g, 78%) as a colorless foam. R_f : 0.52 (EtOAc/Hexanes 3:7); ^1H NMR (d_4 - CD_3OD , 300 MHz, δ) 7.4-7.19 (m, 5 H), 7.15-6.99 (m, 1 H), 6.68-6.55 (m, 4 H) 5.43-5.01 (m, 3 H), 4.6 (bs, 2H), 4.11-4.00 (m, 1 H), 3.18-2.91 (m, 2 H), 1.80-1.55


(bs, 6H) 1.39 (s, 9 H) 1.21-0.89 (m, 6 H); ^{13}C NMR (CH_3OD , 75 MHz, δ , mixture of diastereomers) 171.6, 169.4, 169.3, 161.1, 157.1, 157.0, 137.2, 136.9, 135.4, 135.3, 129.2, 129.1, 128.2, 128.2, 128.0, 120.3, 120.1, 116.0, 115.9, 113.6, 94.8, 79.3, 73.6, 73.5, 66.7, 66.6, 58.6, 58.5, 40.0, 39.9, 36.8, 29.1, 27.7, 27.3, 25.5. MS (Electron spray, m/z , relative intensity) 1023 ($[2\text{M}+1]^+$, 20), 512 ($[\text{M}+1]^+$, 20), 412 ($[\text{M}-\text{Boc}]^+$, 100), 202 (40) HRMS Calcd. for $\text{C}_{24}\text{H}_{30}\text{NO}_5$ ($\text{M}-\text{Boc})^+$ 412.2123 : found 412.2119.

Step E:




A solution of Boc protected amine **33e** (5.2 g, 10.7 mmol) was stirred with HCl (4M, dioxane, 200 mL, 800 mmol, 80 equiv.) until the starting material disappeared to the base line as indicated by TLC (EtOAc/Hex 3:7). The reaction mixture was concentrated *in vacuo* and dried in high vacuum and the residue **33f** was directly used in the next step. ^1H NMR ($\text{d}_4\text{-CD}_3\text{OD}$, 300 MHz, δ) 7.40-3.23 (m, 5 H), 7.07 (q, 1 H, $J=13$ Hz) 6.77-6.6 (m, 3 H), 5.33-5.41 (m, 1 H), 5.3-5.05 (2 AB, 2 H) 3.99-3.85 (m, 1 H) 3.35-2.2 (m, 2 H) 2.00-1.5 (m, 5 H), 1.50-0.80 (m, 6 H); MS (FAB, G/TG-DMSO, m/z , relative intensity): 412 ($[\text{M}+1]^+$, 100); HRMS: Calcd. for $\text{C}_{24}\text{H}_{30}\text{NO}_5$; M^+ 412.2123 : found 412.2139.

Step F:




A solution of $[\text{CpRu}(\eta^6\text{-4-chlorophenylpropionic acid})]\text{PF}_6$ **1c** (2.0 g, 4.03 mmol) in dry DMF (20 mL) was treated with HOBt (835 mg 6.0 mmol, 1.5 equiv.) and Hünigs base (2.06 g, 2.95 mL, 16 mmol, 4.0 equiv.) The reaction mixture was cooled to 0° C and treated with EDCI (1.15 g, 6.0 mmol, 1.5 equiv.) The reaction mixture was stirred at 0° C for 30 min. and the amine hydrochloride was added **33f** (1.8 g, 4.03 mmol, 1.0 equiv.) in dry DMF (10 mL). The reaction mixture was stirred at rt. for 12 h and the DMF was distilled out *vacuo*. The residue was diluted with aq. HCl (1M, 100 mL) and extracted into CH_2Cl_2 (3x100 mL). The combined organic layers were extracted with aq. NaHCO_3 (3x50 mL), brine (100 mL), dried (Na_2SO_4), filtered, concentrated *in vacuo* to yield a brown solid **33g** (3.5 g) which was used for cyclization; MS: Electron spray, m/z , relative intensity) 743 $[(\text{M-PF}_6)^+]$, 100], 304 (60); HRMS: Calcd. for $\text{C}_{38}\text{H}_{41}\text{NO}_6\text{Cl}^{102}\text{Ru}(\text{M-PF}_6)^+$ 744.1666 : found 744.1694.

Step G:




A solution of η^6 -ruthenium complex **33g** (3.5 g, 3.93 mmol) in dry DMF (300 mL) was degassed with dry N_2 and treated with Cs_2CO_3 (6.5 g, 19.95 mmol, 5.0 equiv.) and stirred at rt. for 16 h. The reaction mixture was concentrated *in vacuo* to remove the DMF and the residue was diluted with H_2O (100 mL). The reaction mixture was extracted with CH_2Cl_2 (3x100 mL). The combined CH_2Cl_2 layers were extracted with brine, dried (Na_2SO_4), filtered, concentrated *in vacuo* to yield **33h** which was directly used for photolysis; MS: (Electron spray, m/z, relative intensity) 708 [(M-PF₆)⁺, 100]; HRMS: Calcd. for $C_{38}H_{40}NO_6$ (M-PF₆)⁺: 708.1892; found: 708.1918.

Step H:




A solution of cyclized ruthenium complex **33h** (3.5g, 3.9 mmol) in CH_3CN (60 mL) was degassed and photolyzed in a quartz tube at $\lambda=350$ nm in two batches for 48 h each. The reaction mixture were pooled together and purified by chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{Et}_2\text{O}$ 9/1) to yield cyclic depsipeptide as a mixture of diastereomers. (700 mg, 34%). The diastereomers were separated by additional chromatography (Hexanes/ CH_2Cl_2 / Et_2O 6:3:1) to yield the two diastereomers **33i** (370 mg, 18%) and **33j** (216 mg 11%) as colorless solid. R_f 0.28 (Hexanes: EtOAc: 3:2) ; $[\alpha]_D^{25}$ (c 0.15, CHCl_3 , 20 °C): IR (neat, cm^{-1}) 3329 (w), 2960 (m) 2926 (s), 2854 (s), 1745 (s), 1680 (m), 1589 (m), 1506 (m), 1446 (m), 1365 (w), 1259 (s) 1099 (m), 1030 (s), 800 (s), 752 (m), 698 (w) 619 (w): ^1H NMR (CDCl_3 , 300 MHz, δ) 7.36-7.23 (m, 5 H), 7.18- 6.99 (m, 4 H), 6.81 (d, 1 H, $J=7.5$ Hz), 6.74 (dd, 1 H, $J=2.7, 5.7$ Hz), 6.30 (s, 1 H), 5.75 (d, 1 H, $J=7.2$ Hz), 5.61 (dd, 1 H, $J=2.4$ Hz, 5.4 Hz), 5.18, 5.14 (AB, 2 H, $J=12.3$ Hz), 4.23 (dd, 1 H, $J=4.2$ Hz, 3.3 Hz), 3.26-3.01 (m, 2 H), 2.98-2.85 (m, 2 H), 2.68-2.64 (m, 1H)

2.38-2.34 (m, 1H), 1.96-1.51 (m, 6 H), 1.51-0.96 (M, 5H) ^{13}C NMR: (CDCl_3 , 75 MHz, δ , ppm) 177.3, 171.1, 168.7, 159.8, 155.3, 138.6, 135.4, 134.9, 131.2, 129.7, 129.2, 128.7, 126.6, 126.1, 123.3, 120.8, 120.8, 117.5, 114.2, 71.8, 57.5, 56.9, 41.5, 39.0, 35.7, 32.6, 31.3, 29.0, 27.6, 26.0, 25.9. FAB (NBA/DMSO, m/e , relative intensity) 542 $[(M+1)^+ 100]$, 514 (15), 450 (5), 307 (8), 232 (5), 154.1 (17), 136 (14) HRMS: Calcd for $\text{C}_{33}\text{H}_{36}\text{NO}_6$ $(M+1)^+$ 542.2543: found: 542.2541 CHN Calcd for $\text{C}_{33}\text{H}_{35}\text{NO}_6 \cdot 0.5\text{H}_2\text{O}$; C 71.98% H 6.59% N 2.54%; :Found C 72.56% H 7.05% N 2.63%.

Step I:


A solution of benzyl ester **33i** (360 mg, 0.66 mmol) in $\text{CH}_3\text{OH}/\text{EtOAc}$ (1:1, 50 mL), was treated with $\text{Pd}(\text{OH})_2$ and hydrogenated (50 psi) for 12 h. The reaction mixture was filtered through a plug of celite and the cake was rinsed with $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ (1:1, 50 mL). The filtrate was concentrated *in vacuo* and the residue **33k** (330 mg) was used for coupling without purification. R_f : 0.58 ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ 1:19): MS: (Electron spray, m/z , relative intensity) 827.2 $[(M+1)^+]$, 100], 694 (20), 539 (40), 466 (10), 174 (70). HRMS: Calcd for $\text{C}_{46}\text{H}_{58}\text{N}_4\text{O}_{10}$ $(M+1)^+$ 827.4231: found: 827.4215.

Step J:





A solution of acid **33k** (165 mg, 0.31 mmol) in dry DMF (5.0 mL) and CH_2Cl_2 (5.0 mL) was treated with HOBt (83 mg, 0.46 mmol, 1.5 equiv.) and cooled to 0 °C and Hünigs base (159 mg, 1.23 mmol, 4.0 equiv., 229 μL) was added. To this mixture was added EDCI (89 mg, 0.47 mmol, 1.5 equiv.) and the reaction mixture was stirred at 0° C for 1 h and treated with the amine hydrochloride **B** (159 mg, 0.372 mmol, 1.2 equiv.). The reaction mixture was stirred at rt. for 48 h and concentrated *in vacuo* to remove DMF and CH_2Cl_2 . The residue was diluted with water and extracted with CH_2Cl_2 (3x50 mL). The combined organic layer were extracted with aq. HCl (1M, 3x50 mL), aq. NaOH (1M, 3x50 mL) brine (100 mL) and concentrated *in vacuo*. The residue **33l** was oxidized without further purification.



Step K:



A solution of alcohol **33I** (330 mg, 0.4 mmol) in CH_2Cl_2 (5.0 mL) was treated with Dess-Martin reagent (424 mg, 1.00 mmol, 2.5 equiv.). The reaction mixture was stirred at rt. for 1 h and diluted with aq. NaHCO_3 (50 mL) and aq. $\text{Na}_2\text{S}_2\text{O}_3$ (50 mL). The reaction mixture was stirred at rt for 20 min and the reaction mixture was extracted with CH_2Cl_2 (3x50 mL). The combined organic layers were extracted with brine (50 mL), dried (Na_2SO_4), filtered, concentrated *in vacuo* and the residue was purified by chromatography (SiO_2 , EtOAc/Hexanes 1:1) to yield ketoamide **33** (180 mg, 55%) of a colorless solid. R_f : 0.63 ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ 1:19); MS (Electron spray, m/z relative intensity): 857.2 ($[\text{M}+\text{CH}_3\text{OH}]^+$, 40), 825.2 ($[\text{M}+1]^+$ 100).

Example 34: Preparation of Compound of Formula 34:**Step A:**


A solution of oxidized depsipeptide **33** (160 mg, 0.2 mmol) in dry CH_2Cl_2 (5.0 mL) was treated with TFA (5.0 mL) and stirred at rt. for 7 h. The reaction mixture was concentrated *in vacuo* and the residue was repeatedly dissolved in $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2/\text{Hexanes}$ (1:1:1) and concentrated *in vacuo* several times to yield a tan colored solid **34** (133 mg, 86%) which was dried *in vacuo* MS: (Electron spray, m/z relative intensity): 769.2 $[(M+1)^+, 100]$, 481 (5), 269 (25) 191 (90).

Example 35: Preparation of Compound of Formula 35:**Step A:**



A solution of acid **33k** (165 mg, 0.31 mmol) in dry DMF (5.0 mL) and CH₂Cl₂ (5.0 mL) was treated with HOBt (83 mg, 0.46 mmol; 1.5 equiv) and cooled to 0 °C and Hünigs base (159 mg, 1.23 mmol, 4.0 equiv., 229 μ L) was added. To this mixture was added EDCI (89 mg, 0.47 mmol, 1.5 equiv.) and the reaction mixture was stirred at 0° C for 1 h and treated with the amine hydrochloride **A** (159 mg, 0.372 mmol, 1.2 equiv.). The reaction mixture was stirred at rt. for 48 h and concentrated *in vacuo* to remove DMF and CH₂Cl₂. The residue was diluted with water and extracted with CH₂Cl₂ (3x50 mL) The

combined organic layer was extracted with aq. HCl (1M, 3x50 mL), aq. NaOH (1M, 3x50 mL), brine (100 mL) and concentrated *in vacuo*. The residue **35a** was oxidized without further purification. MS: (Electron spray, *m/z* relative intensity): 798.2 [(M+1)⁺, 30], 479 (10), 391 (20) 180 (100).

Step B:



A solution of alcohol **35a** (190 mg, 0.24 mmol) in CH₂Cl₂ (10 mL) was treated with Dess-Martin reagent (423 mg 1.0 mmol, 4.0 equiv.) and stirred at rt. for 1h. The reaction mixture was diluted with aq. NaHCO₃ (50 mL) and extracted in CH₂Cl₂ (3x50 mL). The combined organic layers were extracted with aq. satd. Na₂S₂O₃, brine (3x50 mL), dried (Na₂SO₄), filtered concentrated *in vacuo* and purified by chromatography (SiO₂, acetone/Hexanes 3:7->1:1 to yield oxidized product **35** (163 mg, 86%) as a colorless solid. MS (Electron spray, *m/z* relative intensity): 796 [(M+1)⁺, 100], 508 (20), 269 (20).


Example 36: Preparation of Compound of Formula 36:**Step A:**

A solution of $\text{BH}_3\cdot\text{THF}$ (1M in THF, 100 mmol, 100 mL, 3.0 equiv.) was added dropwise to a solution of alkene (5.0 g, 35 mmol) in THF (100 mL) at 0°C and stirred for 1h. The reaction mixture was treated with ethanol (20 mL) dropwise. After the evolution of hydrogen gas was complete the reaction mixture was treated with pH 7 buffer (100 mL) and H_2O_2 (30 volumes, 100 mL). The reaction mixture was stirred at rt. for 4 h and quenched with aq. HCl (100 mL). The aqueous layer was extracted with Et_2O (3x100 mL). The combined ether layers were extracted with aq. NaOH (1M, 100 mL), brine (100 mL), dried (MgSO_4), filtered, concentrated *in vacuo* and purified by chromatography (SiO_2 , EtOAc/Hexanes 2/3) to yield alcohol as a colorless liquid (2.9 g, 52%).

A solution of the hydroxylated ester in THF/ H_2O / CH_3OH (100 mL, 1:1:1) was treated with $\text{LiOH}\cdot\text{H}_2\text{O}$ (2.1g, 51.2 mmol, 3.0 equiv.) and stirred at rt. for 3 d. The reaction mixture was concentrated *in vacuo* and the aqueous layer was extracted with ether (2x40 mL). The aqueous layer was acidified to pH ~1 and extracted into EtOAc (3x50 mL). The combined organic layers were extracted with brine (100 mL), dried (MgSO_4) filtered concentrated *in vacuo* and the residue


36b was used as is for coupling in Step B. ^1H NMR (300 MHz, CD_3OD , δ) 3.53 (t, 2 H, $J=6.6$ Hz), 2.72 (t, 2 H, $J=7.2$ Hz), 1.59 (t, 2 H, $J=7.5$ Hz), 1.5 (t, 2 H, $J=7.5$ Hz), 1.38-1.33 (m, 6 H).

Step B:



A solution of ω -hydroxyl heptanoic acid **36b** (1.01g, 6.93 mmol) in CH_2Cl_2 (40 mL) was treated with Hünigs base (1.97 g, 15.24 mmol, 2.2 equiv. 2.81 mL) and amine hydrochloride **33f** (3.1g, 6.93 mmol, 1.0 equiv.). The reaction mixture was cooled to 0 °C and treated with PyBrOP (3.22g, 6.93 mmol, 1.0 equiv.) The reaction mixture was stirred overnight at rt. and the reaction mixture was concentrated *in vacuo*. The residue was purified by chromatography (EtOAc/Hexanes 1:1) to yield depsipeptide **36c** (2.5 g, 66%) as a colorless viscous oil. ^1H NMR (CD_3OD , 400 MHz, δ , ppm) 8.07 (t, 1 H), 7.33-7.21 (m, 4 H), 7.09-7.02 (m, 1 H), 6.67-6.63 (m, 3 H), 5.25-5.06 (m, 1 H), 5.08 (q, 2 H, $J=7.5$ Hz), 4.36-4.33 (m, 1 H), 3.51 (dd, 2 H, $J=5.4$ Hz, 0.9 Hz), 3.11-2.96 (m, 2 H), 2.22-2.17 (m, 1 H), 1.99-0.90 (m, 14 H). ^{13}C NMR : (CD_3OD , 75 MHz, δ , ppm, mixture of diastereomers): 172.1, 172.0, 171.8, 171.1, 170.9, 169.5, 169.3, 157.1, 157.0, 137.3, 137.0, 135.3, 135.2, 129.2, 129.1, 128.2, 128.0, 127.9, 120.3, 120.0, 116.0, 115.9, 113.6, 94.8, 73.6, 73.4, 66.8, 66.7, 60.2, 57.3, 39.6, 36.7, 28.9, 28.0, 25.6, 20.9, 19.5, 13;. MS (FAB, NBA DMSO, m/z rel. int): 562. $[(\text{M}+\text{Na})^+, 20]$, 540. $[(\text{M}+1)^+, 100]$, 412 (15), 240 (50), 112 (80).


Step C:



A solution of alcohol **36c** (2.5g, 4.63 mmol) in dry CH_2Cl_2 (50 mL) was treated with triphenylphosphine (2.67 g, 10.2 mmol, 2.2 equiv.) under N_2 and cooled to 0°C . The reaction mixture was treated with DEAD (1.61g, 9.26 mmol, 2.0 equiv.) in CH_2Cl_2 (30 mL). The reaction mixture was warmed to rt. and stirred for 2h. It was concentrated *in vacuo* and purified by chromatography ($\text{Et}_2\text{O}/\text{Hex}$ 1:3) to yield cyclic product **36d** (530 mg, 21%) as a colorless solid.


MS (FAB, NBA, DMSO, *m/z* rel. int), 522 $[(\text{M}+1)^+, 100]$, 494. (60), 268 (20), 222(20); HRMS calcd. for $\text{C}_{31}\text{H}_{40}\text{NO}_6$: $(\text{M}+1)^+$: 522.2856; Found: 522. 2864.

Step D:



A solution of the benzyl ester (242 mg, 0.47 mmol) in methanol (30 mL) was treated with Pd/C (10 wt %) and hydrogenated on a Parr at 40 psi for 14h. The reaction mixture was filtered through a plug of celite and the filtrate was concentrated *in vacuo* to yield a colorless solid **36e** (181 mg, 93%) which was used for coupling.


Step E:



A solution of the hydrolyzed acid **36e** (167 mg, 0.39 mmol) in CH_2Cl_2 (4.0 mL) was treated with HOOBt (95 mg, 0.58 mmol, 1.5 equiv.) and cooled to 0 °C and Hünigs base (202 mg, 1.56 mmol, 4.0 equiv. 288 μL) was added. To this mixture was added EDCI (111 mg, 0.58 mmol, 1.5 equiv.) and the reaction


mixture was stirred at 0° C for 0.5 h and treated with the amine hydrochloride (186 mg, 0.47 mmol, 1.20 equiv.). The reaction mixture was stored in freezer for 24 h and concentrated *in vacuo* to remove DMF and CH₂Cl₂. The residue was diluted with aq. HCl (2M, 30 mL) and extracted with CH₂Cl₂ (3x50 mL). The combined organic layer was extracted with aq. HCl (2M, 30 mL), aq. NaOH (1M) brine (2x50 mL), dried (MgSO₄) and concentrated *in vacuo*. The residue **36f** (100 mg) was oxidized without further purification. HRMS calcd. for C₄₂H₆₀N₅O₉ (M+1)⁺: 778.4391; Found: 778.4399.

Step F:




A solution of alcohol **36f** (100 mg, 0.13 mmol) in CH₂Cl₂ (5.0 mL) was treated with Dess-Martin reagent (100 mg, 0.23 mmol, 1.8 equiv.). The reaction mixture was stirred at rt. for 2 h and diluted with aq. NaHCO₃ (15 mL) and aq. Na₂S₂O₃ (15 mL). The reaction mixture was concentrated *in vacuo* and the residue was purified by chromatography (SiO₂, acetone/Hexanes: 3:7) to yield ketoamide **36** (61 mg, 61%) as a colorless solid; MS (FAB, NBA/DMSO, *m/z* rel. int): 776 [(M+1)⁺, 100], 731 (10), 598 (25), 570 (15), 485 (20), 358 (20), 247 (50).

Example 37: Preparation of Compound of Formula 37:




37

Step A:


A solution of benzyl ester **33j** (230 mg, 0.42 mmol) in CH₃OH/EtOAc (1:1, 50 mL), was treated with Pd(OH)₂ and hydrogenated (50 psi), for 12 h. The reaction mixture was filtered through a plug of celite and the cake was rinsed with CH₃OH/CH₂Cl₂ (1:1, 50 mL). The reaction mixture was concentrated *in vacuo* and the residue **37a** (177 mg, 93%) was used for coupling without purification.

Step B:





A solution of acid **37a** (177 mg, 0.33 mmol) in dry DMF (5.0 mL) and CH_2Cl_2 (5.0 mL) was treated with HOBt (88 mg, 0.49 mmol, 1.5 equiv) and cooled to 0 °C and Hünigs base (175 mg, 1.35 mmol, 4.0 equiv, 251 μL) was added. To this mixture was added EDCI (95 mg, 0.49 mmol, 1.5 equiv) and the reaction mixture was stirred at 0° C for 1 h and treated with the amine hydrochloride **B** (170 mg, 0.39 mmol, 1.2 equiv.). The reaction mixture was stirred at rt for 48 h and concentrated *in vacuo* to remove DMF and CH_2Cl_2 . The residue was diluted with water and extracted with CH_2Cl_2 (3x50 mL) The combined organic layer was extracted with aq. NaOH (1M, 2x50 mL), brine (100 mL) and concentrated *in vacuo*. The residue **37b** (315 mg) was oxidized without further purification.



Step C:



A solution of alcohol **37b** (315 mg, 0.4 mmol) in CH_2Cl_2 (5.0 mL) was treated with Dess-Martin reagent (424 mg, 1.00 mmol, 2.5 equiv.). The reaction mixture was stirred at rt. for 1 h and diluted with aq. NaHCO_3 (50 mL) and aq. $\text{Na}_2\text{S}_2\text{O}_3$ (50 mL). The reaction mixture was stirred at rt. for 20 min and the reaction mixture was extracted with CH_2Cl_2 (3x50 mL). The combined organic layers were extracted with brine, dried (Na_2SO_4), filtered concentrated *in vacuo* and the residue was purified by chromatography (SiO_2 , EtOAc/Hexanes 1:1) to yield ketoamide **37** (210 mg, 66%) of a colorless solid. R_f : 0.63 ($\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ 1:19); MS: (Electron spray, m/z relative intensity): 857 ($[\text{M}+\text{CH}_3\text{OH}]^+$, 33), 825 ($[\text{M}+1]^+$, 40), 191 (100).

Example 38: Preparation of Compound of Formula 38:**Step A:**


A solution of oxidized depsipeptide **37** (200 mg, 0.24 mmol) in dry CH_2Cl_2 (5.0 mL) was treated with TFA (5.0 mL) and stirred at rt. for 7 h. The reaction mixture was concentrated *in vacuo* and the residue was repeatedly dissolved in $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2/\text{Hexanes}$ (1:1:1) and concentrated *in vacuo* several times to yield a tan colored solid **38** (130 mg, 87%) which was dried *in vacuo*; MS: (Electron spray, m/z relative intensity): 769 ($[\text{M}+1]^+$, 45), 294 (45), 191 (100).

Example 39: Preparation of Compound of Formula 39:**Step A:**

A solution of acid **22** (40 mg, 0.06 mmol) in CH_2Cl_2 (0.5 mL) and DMF (0.5 mL) was cooled to 0°C and treated with $\text{Me}_2\text{NH}\cdot\text{HCl}$ (15 mg, 0.18 mmol, 3.0 equiv) and Hünigs base (31 mg, 0.24 mmol, 44 μL , 4.0 equiv). The reaction mixture was then treated with PyBrOP (55 mg, 0.12 mmol, 2.0 equiv) and stored for 12 h in the freezer. The yellow reaction mixture was concentrated *in vacuo* and the residue was purified by chromatography (SiO_2 , EtOAc/Hexanes gradient 3:2 \rightarrow 1:0) to obtain impure product which was purified once again using (acetone/Hexanes 1:6) to yield dimethyl amide **39** as a colorless solid (14 mg,

35%). MS: (Electron spray, *m/z* relative intensity): 791 [(M+1)⁺, 50], 391 (40), 276 (50), 176 (100).

Example 40: Preparation of Compound of Formula 40:












40

General procedure for solid-phase coupling reactions:

The synthesis was done in a reaction vessel which was constructed from a polypropylene syringe cartridge fitted with a polypropylene frit at the bottom. The Fmoc-protected amino acids were coupled under standard solid-phase techniques. Each reaction vessel was loaded with 100 mg of the starting Fmoc-Sieber resin (approximately 0.035 mmol). The resin was washed with 2 mL portions of DMF (2 times). The Fmoc protecting group was removed by treatment with 2 mL of a 20 % v/v solution of piperidine in DMF for 20 min. The resin was washed with 2 mL portions of DMF (4 times). The coupling was done in DMF (2 mL), using 0.12 mmol of Fmoc-amino acid, 0.12 mmol of HATU and 0.24 mmol of DIPEA. After shaking for 2 h, the reaction vessel was drained and the resin was washed with 2 mL portions of DMF (4 times). The coupling cycle was repeated with the next Fmoc-amino acid or capping group.

Scheme 10:







Fmoc-Sieber resin **40a** (0.035 mmol) was treated with 2 mL of a 20 % v/v solution of piperidine in DMF for 20 min. followed by washing with 2 mL portions of DMF (4 times). DMF (2 mL) was added to the resin followed by Fmoc-phenylglycine (0.12 mmol), HATU (0.12 mmol) and DIPEA (0.24 mmol). After shaking at room temperature for 2 h, the resin was washed with 2 mL portions of DMF (4 times) to afford resin-bound compound **40b**. Resin-bound compound **40b** was treated with 2 mL of a 20 % v/v solution of piperidine in DMF for 20 min. followed by washing with 2 mL portions of DMF (4 times). DMF (2 mL) was added to the resin followed by Fmoc-glycine (0.12 mmol), HATU (0.12 mmol) and DIPEA (0.24 mmol). After shaking at room temperature for 2 h, the resin was washed with 2 mL portions of DMF (4 times) to afford resin-bound compound **40c**. Resin-bound compound **40c** was treated with 2 mL of a 20 % v/v solution of piperidine in DMF for 20 min. followed by washing with 2 mL portions of DMF (4 times). DMF (2 mL) was added to the resin followed by N-Fmoc-propylisoserine (0.12 mmol), HATU (0.12 mmol) and DIPEA (0.24 mmol). After shaking at room temperature for 2 h, the resin was washed with 2 mL portions of DMF (4 times) to afford resin-bound compound **40d**. Resin-bound compound **40d** was treated with 2 mL of a 20 % v/v solution of piperidine in DMF for 20 min. followed by washing with 2 mL portions of DMF (4 times). DMF (2 mL) was added to the resin followed by Fmoc-lysine(Dde) (0.12 mmol), HATU (0.12 mmol) and DIPEA (0.24 mmol). After shaking at room temperature for 2 h, the resin was washed with 2 mL portions of DMF (4 times) to afford resin-bound compound **40e**. Resin-bound compound **40e** was treated with 2 mL of a 20 % v/v solution of piperidine in DMF for 20 min. followed by washing with 2 mL portions of DMF (4 times). DMF (2 mL) was added to the resin followed by Fmoc-cyclohexylglycine (0.12 mmol), HATU (0.12 mmol) and DIPEA (0.24 mmol). After shaking at room temperature for 2 h, the resin was washed with 2 mL portions of DMF (4 times) to afford resin-bound compound **40f**. Resin-bound compound **40f** was treated with 2 mL of a 20 % v/v solution of piperidine in DMF for 20 min. The resin was washed with 2 mL portions of DMF (4 times) to provide resin-bound compound **40g**. Resin-bound compound **40g** was treated with 2 mL portions of a 2 % v/v solution of hydrazine

in DMF for 5 min. (3 times). The resin was washed with 2 mL portions of DMF (4 times) to provide resin-bound compound **40h**. Resin-bound compound **40h** was treated with 0.035 mmol of glutaric acid, 0.07 mmol of HATU and 0.14 mmol of DIPEA in 2 mL of DMF at room temperature for 16 h. The resin was washed with 2 mL portions of DMF (4 times), THF (4 times) and DCM (4 times) to provide resin-bound compound **40i**. Resin-bound compound **40i** was treated with a solution of 0.14 mmol of Dess-Martin periodinane and 0.14 mmol of t-BuOH in 2 mL of DCM at room temperature for 4 h. The resin was washed with 2 mL portions of a 20 % v/v solution of iPrOH in DCM, THF, a 50 % v/v solution of THF in water (4 times), THF (4 times) and DCM (4 times) to provide resin-bound compound **40j**. The resin-bound compound **40j** was treated with 4 mL of a 2 % v/v solution of TFA in DCM for 5 min. The filtrate was added to 1 mL of AcOH and the solution was concentrated by vacuum centrifugation to provide compound **40** (0.0117 g, 48 % yield). MS (LCMS-Electrospray) 698.2 MH⁺.


Example 41 – 53: Preparation of Compounds of Formula 41 to 53:




41







42




43




44







49




50



51




52




Compounds 41-53 were synthesized using solid phase methodology similar to the procedure outlined for the synthesis of Example 40.

Example 54: Preparation of Compound of Formula 54:




Step A:



To a stirred solution of Boc-Cyclohexylglycine-OH (2.33 g, 9.07 mmol) in DMF (20 mL) and CH₂Cl₂ (20 mL) was added HOBT (1.48 g, 9.07 mmol), EDCI (1.91 g, 9.97 mmol) and NMM (2.99 mL, 27.2 mmol). The solution was stirred at -20°C for 10 minutes, followed by addition of H-Lys(Z)-OMe.HCl and stirred for half an hour at -20°C and kept in freezer overnight. The solution was then concentrated to dryness, followed by extraction with EtOAc, saturated NaHCO₃.


The combined organic layer was washed with H₂O, brine, dried over Na₂SO₄ and concentrated to dryness to give a white solid (4.83 g, MH⁺=534.1).

Step B:



To a stirred solution of **54b** (4.86 g, 8.76 mmol) in MeOH (10 mL) and H₂O (7 mL) was added LiOH (70 mg, 11.4 mmol). The white precipitate was formed and the solution was allowed to stir at room temperature overnight and then concentrated to dryness. This crude material was then partitioned between CH₂Cl₂ and water. The organic layer was separated and washed with brine, dried over Na₂SO₄, filtered and concentrated to dryness to give **54c** (4.55 g, MH⁺=520.1).


Step C:



To a stirred cooling solution of **54c** (4.3 g, 8.27 mmol) in DMF (40 mL) and CH₂Cl₂ (40 mL) at -20 °C was added HOBt (1.35 g, 8.27 mmol), EDCI (1.74 g, 9.1 mmol) and NMM (2.73 mL, 8.27 mmol). The resulting solution was stirred at -20 °C for 10 minutes, followed by addition of amine **G** (2.32 g, 8.27 mmol) and


stirred at $-20\text{ }^{\circ}\text{C}$ for half an hour and kept in freezer overnight. The work up procedure from step A was followed to give a **54d** (6.21 g, $\text{MH}^+=746.2$).

Step D:




The solution of **54d** (6.16 g, 8.26 mmol) in 4N HCl/Dioxane (40 mL) was stirred at room temperature for 1 hr and concentrated to dryness to give a crude product **54e** (5.70 g, 100% yield, $\text{MH}^+=646.3$).

Step F:




To a stirred solution of **54f** (6.9 g, 7.15 mmol) in absolute EtOH (350 mL), was added 10% Pd/C (2.8 g) in 50% H₂O (w/w). The resulting solution was purged with H₂ and stirred under H₂ balloon overnight. The solution was then filtered through celite and the filtrate was washed with EtOH/CH₂Cl₂ and then concentrated to dryness to give a white solid (1.44 g). The solid was washed with 25% H₂O/ MeOH and filtered through sintered funnel, then freeze-dried and lyophilized to give **54g** (4.12 g, 77.5% yield, $MH^+ = 743.2$).

Step G:



To a stirred cooling solution of **54g** (0.5 g, 6.7 mmol) in DMF (50 mL) and CH_2Cl_2 (50 mL) at $-20\text{ }^\circ\text{C}$, was added HOBt (0.219 g, 1.34 mmol), EDCI (0.271 g, 1.41 mmol) and NMM (0.296 mL, 2.69 mmol). The resulting solution was stirred at $-20\text{ }^\circ\text{C}$ for 25 minutes and then kept in freezer overnight. The solution was concentrated to dryness, followed by extraction with EtOAc saturated NaHCO_3 . The combined organic layer was then concentrated to dryness to give **54h** (254 mg, $\text{MH}^+=725.2$).

Step H:

To a stirred solution of **54h** (0.2 g, 0.27 mmol) in anhydrous CH_2Cl_2 (20 mL), was added Dess-Martin periodinane (0.234 g, 0.55 mmol). The resulting solution was stirred at room temperature for 1 hr. To this solution was added dropwise over half an hour the solution of H_2O (0.010 mL) in CH_2Cl_2 (20 mL) and stirred vigorously for additional 2 hrs. The solution was then stirred for half an hour with 50% $\text{Na}_2\text{S}_2\text{O}_3$ /50% sat. NaHCO_3 . The organic layer was separated and washed with H_2O , brine, dried over Na_2SO_4 , filtered, concentrated to dryness and purified by column chromatography on silica gel, eluting with 10% $\text{MeOH}/\text{CH}_2\text{Cl}_2$ to yield **54** (17 mg, 62% $\text{MH}^+ = 723.2$).

Assay for HCV Protease Inhibitory Activity:

Spectrophotometric Assay: Spectrophotometric assays for the HCV serine protease was performed on the inventive compounds by following the procedure described by R. Zhang *et al*, *Analytical Biochemistry*, **270** (1999) 268-275, the disclosure of which is incorporated herein by reference. The assay based on the proteolysis of chromogenic ester substrates is suitable for the continuous monitoring of HCV NS3 protease activity. The substrates were derived from the P side of the NS5A-NS5B junction sequence (Ac-DTEDVVX(Nva), where X = A or P) whose C-terminal carboxyl groups were esterified with one of four different

chromophoric alcohols (3- or 4-nitrophenol, 7-hydroxy-4-methyl-coumarin, or 4-phenylazophenol). Presented below are the synthesis, characterization and application of these novel spectrophotometric ester substrates to high throughput screening and detailed kinetic evaluation of HCV NS3 protease inhibitors.

Materials and Methods:

Materials: Chemical reagents for assay related buffers were obtained from Sigma Chemical Company (St. Louis, Missouri). Reagents for peptide synthesis were from Aldrich Chemicals, Novabiochem (San Diego, California), Applied Biosystems (Foster City, California) and Perseptive Biosystems (Framingham, Massachusetts). Peptides were synthesized manually or on an automated ABI model 431A synthesizer (from Applied Biosystems). UV/VIS Spectrometer model LAMBDA 12 was from Perkin Elmer (Norwalk, Connecticut) and 96-well UV plates were obtained from Corning (Corning, New York). The prewarming block was from USA Scientific (Ocala, Florida) and the 96-well plate vortexer was from Labline Instruments (Melrose Park, Illinois). A Spectramax Plus microtiter plate reader with monochromator was obtained from Molecular Devices (Sunnyvale, California).

Enzyme Preparation: Recombinant heterodimeric HCV NS3/NS4A protease (strain 1a) was prepared by using the procedures published previously (D. L. Sali *et al*, *Biochemistry*, 37 (1998) 3392-3401). Protein concentrations were determined by the Biorad dye method using recombinant HCV protease standards previously quantified by amino acid analysis. Prior to assay initiation, the enzyme storage buffer (50 mM sodium phosphate pH 8.0, 300 mM NaCl, 10% glycerol, 0.05% lauryl maltoside and 10 mM DTT) was exchanged for the assay buffer (25 mM MOPS pH 6.5, 300 mM NaCl, 10% glycerol, 0.05% lauryl maltoside, 5 μ M EDTA and 5 μ M DTT) utilizing a Biorad Bio-Spin P-6 prepacked column.

Substrate Synthesis and Purification: The synthesis of the substrates was done as reported by R. Zhang *et al*, (*ibid.*) and was initiated by anchoring Fmoc-Nva-OH to 2-chlorotrityl chloride resin using a standard protocol (K. Barlos *et al*, *Int. J. Pept. Protein Res.*, 37 (1991), 513-520). The peptides were subsequently

assembled, using Fmoc chemistry, either manually or on an automatic ABI model 431 peptide synthesizer. The N-acetylated and fully protected peptide fragments were cleaved from the resin either by 10% acetic acid (HOAc) and 10% trifluoroethanol (TFE) in dichloromethane (DCM) for 30 min, or by 2% trifluoroacetic acid (TFA) in DCM for 10 min. The combined filtrate and DCM wash was evaporated azeotropically (or repeatedly extracted by aqueous Na_2CO_3 solution) to remove the acid used in cleavage. The DCM phase was dried over Na_2SO_4 and evaporated.

The ester substrates were assembled using standard acid-alcohol coupling procedures (K. Holmber *et al*, *Acta Chem. Scand.*, **B33** (1979) 410-412). Peptide fragments were dissolved in anhydrous pyridine (30-60 mg/ml) to which 10 molar equivalents of chromophore and a catalytic amount (0.1 eq.) of para-toluenesulfonic acid (pTSA) were added. Dicyclohexylcarbodiimide (DCC, 3 eq.) was added to initiate the coupling reactions. Product formation was monitored by HPLC and found to be complete following 12-72 hour reaction at room temperature. Pyridine solvent was evaporated under vacuum and further removed by azeotropic evaporation with toluene. The peptide ester was deprotected with 95% TFA in DCM for two hours and extracted three times with anhydrous ethyl ether to remove excess chromophore. The deprotected substrate was purified by reversed phase HPLC on a C3 or C8 column with a 30% to 60% acetonitrile gradient (using six column volumes). The overall yield following HPLC purification was approximately 20-30%. The molecular mass was confirmed by electrospray ionization mass spectroscopy. The substrates were stored in dry powder form under desiccation.

Spectra of Substrates and Products: Spectra of substrates and the corresponding chromophore products were obtained in the pH 6.5 assay buffer. Extinction coefficients were determined at the optimal off-peak wavelength in 1-cm cuvettes (340 nm for 3-Np and HMC, 370 nm for PAP and 400 nm for 4-Np) using multiple dilutions. The optimal off-peak wavelength was defined as that wavelength yielding the maximum fractional difference in absorbance between substrate and product (product OD - substrate OD)/substrate OD).

Protease Assay: HCV protease assays were performed at 30°C using a 200 μ l reaction mix in a 96-well microtiter plate. Assay buffer conditions (25 mM MQPS pH 6.5, 300 mM NaCl, 10% glycerol, 0.05% lauryl maltoside, 5 μ M EDTA and 5 μ M DTT) were optimized for the NS3/NS4A heterodimer (D. L. Sali *et al, ibid.*). Typically, 150 μ l mixtures of buffer, substrate and inhibitor were placed in wells (final concentration of DMSO = 4 % v/v) and allowed to preincubate at 30 °C for approximately 3 minutes. Fifty μ l of prewarmed protease (12 nM, 30°C) in assay buffer, was then used to initiate the reaction (final volume 200 μ l). The plates were monitored over the length of the assay (60 minutes) for change in absorbance at the appropriate wavelength (340 nm for 3-Np and HMC, 370 nm for PAP, and 400 nm for 4-Np) using a Spectromax Plus microtiter plate reader equipped with a monochromator (acceptable results can be obtained with plate readers that utilize cutoff filters). Proteolytic cleavage of the ester linkage between the Nva and the chromophore was monitored at the appropriate wavelength against a no enzyme blank as a control for non-enzymatic hydrolysis. The evaluation of substrate kinetic parameters was performed over a 30-fold substrate concentration range (~6-200 μ M). Initial velocities were determined using linear regression and kinetic constants were obtained by fitting the data to the Michaelis-Menten equation using non-linear regression analysis (Mac Curve Fit 1.1, K. Raner). Turnover numbers (k_{cat}) were calculated assuming the enzyme was fully active.

Evaluation of Inhibitors and Inactivators: The inhibition constants (K_i) for the competitive inhibitors Ac-D-(D-Gla)-L-I-(Cha)-C-OH (27), Ac-DTEDVVA(Nva)-OH and Ac-DTEDVVP(Nva)-OH were determined experimentally at fixed concentrations of enzyme and substrate by plotting v_o/v_i vs. inhibitor concentration ($[I]_o$) according to the rearranged Michaelis-Menten equation for competitive inhibition kinetics: $v_o/v_i = 1 + [I]_o / (K_i (1 + [S]_o / K_m))$, where v_o is the uninhibited initial velocity, v_i is the initial velocity in the presence of inhibitor at any given inhibitor concentration ($[I]_o$) and $[S]_o$ is the substrate concentration used. The resulting data were fitted using linear regression and the resulting slope, $1/(K_i(1+[S]_o/K_m))$, was used to calculate the K_i value.

The obtained K_i values for the various macrocycles of the present invention are given in the afore-mentioned **Table 1** wherein the compounds have been arranged in the order of ranges of K_i values. From these test results, it would be apparent to the skilled artisan that the compounds of the invention have excellent utility as NS3-serine protease inhibitors.

Cell Bioassay Method: The cell bioassays for the HCV serine protease was performed on the inventive compounds by following the procedure described by S. Agrawal *et al*, "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay", *Hepatology* Supplement to Volume 30 (No. 4, Part 2, October 1999), *Abstract No. 615* (Proceedings of AASLD 50th Annual Meeting, Dallas, Texas, November 5-9, 1999), the disclosure of which is incorporated herein by reference. The assay was performed in HeLa/Huh7 cells that were co-transfected with a plasmid that expresses a reporter protein substrate containing the NS5A/5B cleavage recognition sequence and an 1BNS4A₂₁₋₃₂ GS-GSNS₃₋₈₁ I17K expression vector and YFPn1 as a internal standard protein to control cytotoxicity. Protease activity was measured by SDS-PAGE of total cell lysates followed by Western blot detection using a monoclonal antibody directed against the reporter substrate. Quantitation of substrate cleavage was performed by scanning the immunoblot on the phosphoimager.

Materials:

Plasmid DNAs

pBFP-5A/5B-GFP: The reporter gene that expresses the substrate encodes a fusion protein comprised of an N' terminal blue fluorescent protein (BFP) domain and a C' terminal green fluorescent protein (GFP) domain, separated by a 25 amino acids derived from the NS5A/5B cleavage recognition sequence. Both GFP and BFP are essentially homologous autofluorescent proteins that emit green or blue light, respectively, when excited by UV light of the appropriate wavelength. Four amino acid substitutions in the chromophore of GFP alter the emission wavelength and convert the protein to BFP.

The substrate and the resulting GFP and BFP products can be detected in cell lysates by immunologic methods using a monoclonal antibody that recognizes both proteins.

The BFP-5A/5B-GFP reporter gene contains the BFP and GFP autofluorescent protein coding sequences (Quantum Biotechnologies, Inc., Montreal, Canada) separated by the NS5A/5B cleavage recognition sequence, cloned between the Nhe I and Bam HI restriction endonuclease sites of the pQBI25 cloning vector (Quantum Biotechnologies, Inc.). Expression of the fusion protein is under the control of the CMV IE promoter-enhancer. The bovine growth hormone p (A) sequence of the vector provides the polyadenylation signal for the mRNA. The NS5A/5B cleavage sequence is: SSGADTEDVVCCSMSYTWGALVTP. DNA sequencing was used to validate the clone.

P1BOO2: 1bNS4A21-32GS-GS NS 3-81 I17K: The subtype 1b protease was cloned as an XbaI/NotI fragment behind the CMV promoter in vector pC1neo.

YFPn1: YFPn1 was purchased from CLONTECH (Palo Alto, California). Addition of third plasmid to the transfection supplies an internal standard protein to control for cytotoxicity and does not affect percentage of protease cleavage.

Plasmid DNAs were maintained and propagated in DH5 α cells (obtained from Life Technologies) in LB medium under the appropriate antibiotic selection, and purified using QIAfilter Plasmid Kits (Qiagen, Valencia, California).

Cell Culture:

HeLa cells were maintained and propagated in Eagle's Minimum Essential Media (EMEM; BioWhittaker, Walkersville, Maryland) supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, and 100 u/ml penicillin-streptomycin (BioWhittaker), 2% NaHCO₃.

Huh7 cells were maintained and propagated in Dulbecco's Modified Eagle's medium (DMEM; BioWhittaker) supplemented with 10% fetal calf serum (FCS), 100u/ml penicillin-streptomycin (BioWhittaker) and 5 ml NEAA (100x; BioWhittaker)/L.

SOP Procedure

Day preceding transfection:

HeLa cells were seeded in 24 well plates (Falcon 3047 plates) at a density of 6×10^4 cells/well and grown overnight at 37°C in a 5% CO₂ incubator.

Day of transfection:

Plasmid DNAs were diluted to a final concentration of 0.05 µg/µl in nuclease free water (Promega, Madison, Wisconsin, cat # P119C). 0.75 µg BFP-5A/5B-GFP was combined and mixed with 0.175 µg P1B002 (0.23X) and 0.02 µg of YFPn1. The DNAs were brought to a final volume of 60 µl with EMEM lacking FBS, glutamine, and antibiotics. A ratio of 5 µl volumes of SuperFect Reagent (Qiagen, cat # 301305) per total µgs of DNA was added and the mixture vortexed about 10 seconds and incubated 10 min. at room temperature to allow complex formation. While complex formation was taking place, growth medium from cell culture plates was aspirated and cells washed 1X with 1 ml PBS without Ca²⁺, Mg²⁺ (BioWhittaker). 350 µl EMEM (supplemented with appropriate supplements-compleat medium) was added to the tube containing the transfection complexes and the mixture pipetted up and down 2-3 times. Total volume was transferred to one well of the 24 well culture plate. The HeLa cells were incubated with the transfection complexes for about 3 hr. at 37°C and 5% CO₂. The media containing the transfection complexes was removed from the cells by aspiration. The cells were washed once in about 1 ml PBS, the PBS was aspirated and 495 µl of complete EMEM was added followed by 5 µl compound/well. The cells were incubated 22-24 hr. at 37°C and 5% CO₂.

Preparation of Cell Lysates

The medium from each well was aspirated and washed once 1x with DPBS. Cells were harvested in 100 µl of 1x Tris-SDS-BME sample buffer (OWL separation system, Portsmouth, New Hampshire, cat # ER33) and transferred to microcentrifuge tubes. It was then boiled 3-5 min. to lyse cells. Loading was done at 10 µl/well on SDS-PAGE gel. The lysates were resolved by electrophoresis on 10 cm x 10 cm 12.5% SDS-PAGE (Owl Scientific, cat # OG-0125B) run at 30 mamp in Tris-Glycine-SDS buffer (Owl Scientific). Prior to use, PVDF membrane

(Immobilon-P; .45 μ m pore size; Millipore, Bedford, Massachusetts) was soaked in 100% methanol for 10 seconds and then the blot was placed in distilled water. The proteins were transferred to PVDF filter membranes (0.45 μ m, Millipore) at 108 mamp per gel for 90 minutes using a semi-dry electroblotter.

Detection of Proteins by ECF Western Blot (Amersham Pharmacia Biotech, Little Chalfont, England), catalog #RPN 5780). The PVDF filter membranes were blocked by 5% blocking reagent (from kit) in ~10 ml PBS containing 0.05% Tween 20, pH 7.4 (Sigma Chemicals, St. Louis, Missouri, cat # 3563) for overnight at 2-4 C in refrigerator. The next day, the membranes were rinsed briefly twice with TPBS containing 0.05% Tween 20 washing buffer, then washed three times each time 5 min. in PBS containing 0.05% Tween 20, pH 7.4. The membranes were incubated in 12 mls of a 1:3000 dilution of anti-GFP monoclonal antibody for 30 minutes (Clontech, Palo Alto, California) in PBS containing 0.05% Tween 20, pH 7.4 while at the same time 1% BSA (Albumin, bovine cat # A-2153 from Sigma) was added to reduce background. The membranes were washed briefly twice with TPBS, then thrice, for 5 min. each time, in TPBS washing buffer. The membranes were incubated in 12 mls of a 1:600 dilution anti fluorescein-linked anti mouse Ig in TPBS for 30 minutes. The membranes were washed briefly with TPBS twice, then for 5 min. in TPBS washing buffer thrice. For signal amplification with ECF substrate membranes were incubated in 10 ml of 1:2500 anti fluorescein alkaline phosphatase conjugate for 30 minutes. The membranes were rinsed briefly with TPBS twice, then 5 min. in TPBS washing buffer thrice. The ECF substrate solution was prepared as per manufacturer's instructions (aliquot and freeze), membranes were incubated for 2-3 minutes, excess reagent was drained off, then were blotted with filter papers, air-dried for 9-10 minutes and then scanned.

Scanning the membrane: The blot was placed on the glass of phosphorimager Storm 860. The blue chemiluminescent was set up, 200 pixels size, 700 PMT voltage. The file was opened in ImageQuant and quantitated by creating squares around the bands representing the substrate (S), the product (P) and the internal control (IC). The % cleavage of the substrate was measured as $P/(S+P) \times 100$.

The inhibition in cleavage due to drug was measured compared duplicate to drug controls included on each blot. A report was created in Excel. The results for some of the compounds are given below:

Compound of Example 36: $EC_{50} = 9\mu\text{m}$


Compound of Example 35: $EC_{50} = 20\mu\text{m}$

From these test results, it would be apparent to the skilled artisan that the compounds of the invention have excellent utility as NS3-serine protease inhibitors.

Claims

What is claimed is:

1. A macrocyclic compound, including enantiomers, stereoisomers, rotomers and tautomers of said compound, and pharmaceutically acceptable salts or solvates of said compound having the general structure shown in Formula I:



Formula I

wherein:

E, X and Y may be independently present or absent, and if present are independently selected from the moieties: alkyl, aryl, alkyl-aryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl, alkyl ether, alkyl-aryl ether, aryl ether, alkyl amino, aryl amino, alkyl-aryl amino, alkyl sulfide, alkyl-aryl sulfide, aryl sulfide, alkyl sulfone, alkyl-aryl sulfone, aryl sulfone, alkyl-alkyl sulfoxide, alkyl-aryl sulfoxide, alkyl amide, alkyl-aryl amide, aryl amide, alkyl sulfonamide, alkyl-aryl sulfonamide, aryl sulfonamide, alkyl urea, alkyl-aryl urea, aryl urea, alkyl carbamate, alkyl-aryl carbamate, aryl carbamate, alkyl -hydrazide, alkyl-aryl hydrazide, alkyl hydroxamide, alkyl-aryl hydroxamide, alkyl sulfonyl, aryl sulfonyl, heteroalkyl sulfonyl, heteroaryl sulfonyl, alkyl carbonyl, aryl carbonyl, heteroalkyl carbonyl, heteroaryl carbonyl, alkoxy carbonyl, aryloxy carbonyl, heteroaryloxy carbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylamino carbonyl or a combination thereof, with the proviso that E, X and Y may optionally be additionally substituted with moieties selected from the group consisting of aromatic, alkyl, alkyl-aryl, heteroalkyl, aryl-heteroaryl, alkyl-

heteroaryl, cycloalkyl, alkyl ether, alkyl-aryl ether, alkyl sulfide, alkyl-aryl sulfide, alkyl sulfone, alkyl-aryl sulfone, alkyl amide, alkyl-aryl amide, alkyl sulfonamide, alkyl amines, alkyl-aryl amines, alkyl-aryl sulfonamide, alkyl urea, alkyl-aryl urea, alkyl carbamate, alkyl-aryl carbamate, halogen, hydroxyl amino, alkyl carbazate, aryl carbazate;

$R^1 = COR^5$ or $B(OR)_2$, wherein $R^5 = H, OH, OR^8, NR^9R^{10}, CF_3, C_2F_5, C_3F_7, CF_2R^6, R^6, COR^7$ wherein $R^7 = H, OH, OR^8, CHR^9R^{10}$, or NR^9R^{10} , wherein R^6, R^8, R^9 and R^{10} are independently selected from the group consisting of H, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, cycloalkyl, arylalkyl, heteroarylalkyl, $CH(R^1)COOR^{11}$, $CH(R^1)CONR^{12}R^{13}$, $CH(R^1)CONHCH(R^2)COO R^{11}$, $CH(R^1)CONHCH(R^2)CONR^{12}R^{13}$, $CH(R^1)CONHCH(R^2)R^1$, $CH(R^1)CONHCH(R^2)CONHCH(R^3)COO R^{11}$, $CH(R^1)CONHCH(R^2)CONHCH(R^3)CONR^{12}R^{13}$, $CH(R^1)CONHCH(R^2)CONHCH(R^3)CONHCH(R^4)COO R^{11}$, $CH(R^1)CONHCH(R^2)CONHCH(R^3)CONHCH(R^4)CONR^{12}R^{13}$, $CH(R^1)CONHCH(R^2)CONHCH(R^3)CONHCH(R^4)CONHCH(R^5)COO R^{11}$, $CH(R^1)CONHCH(R^2)CONHCH(R^3)CONHCH(R^4)CONHCH(R^5) CONR^{12}R^{13}$, wherein $R^1, R^2, R^3, R^4, R^5, R^{11}, R^{12}, R^{13}$, and R^1 are independently selected from a group consisting of H, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, alkyl-aryl, alkyl-heteroaryl, aryl-alkyl and heteroaralkyl;

Z is selected from O, N, or CH;

W may be present or absent, and if W is present, W is selected from C=O, C=S, SO_2 or C=NR;

Q is $(NR)_p$, O, S, CH_2 , CHR, CRR' or a double bond towards V;

A is O, CH_2 , $(CHR)_p$, $(CHR-CHR')_p$, $(CRR')_p$, NR, S, SO_2 , C=O or a bond;

G is $(CH_2)_p$, $(CHR)_p$, $(CRR')_p$, NR, O, S, SO_2 , $S(O)_2NH$, C=O, or a double bond towards E or V;

V is CH, CR or N;

p is a number from 0 to 6; and

R, R', R², R³ and R⁴ are independently selected from the group consisting of H; C1-C10 alkyl; C2-C10 alkenyl; C3-C8 cycloalkyl; C3-C8 heterocycloalkyl,

aryl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro; heteroaryl; alkyl-aryl; alkyl-heteroaryl; (cycloalkyl)alkyl and (heterocycloalkyl)alkyl, wherein said cycloalkyl is made of three to eight carbon atoms, and zero to six oxygen, nitrogen, sulfur, or phosphorus atoms, and said alkyl is of one to six carbon atoms;

with said alkyl, heteroalkyl, alkenyl, heteroalkenyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties may be optionally substituted, with said term

"substituted" referring to optional and suitable substitution with one or more moieties selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, heterocyclic, halogen, hydroxy, thio, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, sulfonamide, sulfoxide, sulfone, sulfonyl urea, hydrazide, hydroxamate and thiourea.

2. The compound of claim 1, wherein $R^1 = COR^5$, and R^5 is H, OH, $COOR^8$, or $CONR^9R^{10}$.


3. The compound of claim 2, wherein $R^1 = COCONR^9R^{10}$, and R^9 is H, R^{10} is H, $CH(R^1)COOR^{11}$, $CH(R^1)CONR^{12}R^{13}$, $CH(R^1)CONHCH(R^2)COOR^{11}$, $CH(R^1)CONHCH(R^2)CONR^{12}R^{13}$, or $CH(R^1)CONHCH(R^2)(R')$.

4. The compound of claim 3, wherein $R^{10} = CH(R^1)CONHCH(R^2)COOR^{11}$, $CH(R^1)CONHCH(R^2)CONR^{12}R^{13}$, or $CH(R^1)CONHCH(R^2)(R')$, wherein R^1 is H or alkyl, and R^2 is selected from the group consisting of phenyl, substituted phenyl, hetero atom-substituted phenyl, thiophenyl, cyclohexyl, cyclopentyl, cyclopropyl, piperidyl pyridyl and 2-indanyl.


5. The compound of claim 4, wherein R^1 is H.

6. The compound of claim 5, wherein $R^2 =$ phenyl, thiophenyl, cyclohexyl, 2-indanyl, cyclopentyl, pyridyl, phenyl(4-HNSO₂NH₂), R^{11} is H or *tert*-butyl, R^{12} and R^{13} are methyl, and R' is hydroxymethyl or *tert*-butoxymethyl.


7. The compound of claim 1, wherein R^2 is selected from the group consisting of the following moieties:



8. The compound of claim 7 wherein $R^1 = COR^5$, and R^5 is H, OH, $COOR^8$, or $CONR^9R^{10}$.
9. The compound of claim 8 wherein V is CH.
10. The compound of claim 9 wherein Q is NR or O.
11. The compound of claim 10 wherein G is CH_2 .
12. The compound of claim 11 wherein A is O, NR, $CH=CH$ or CH_2 .
13. The compound of claim 12 wherein E is alkyl, aryl, heteroalkyl, heteroaryl, alkyl, aryl, or cycloalkyl.
14. The compound of claim 13 wherein E is selected from the group consisting of the moieties:



15. The compound of claim 14 wherein R^3 is selected from the group consisting of the moieties:



wherein R^{30} = H, CH_3 or other alkyl groups;

R^{31} = OH, O-alkyl, NH_2 , N-alkyl; and


R^{32} and R^{33} may be the same or different and are selected independently from H, F, Cl, Br and CH_3 .

16. The compound of claim 15 wherein $Z = \text{N}$ and $R^4 = \text{H}$.

17. The compound of claim 16 wherein W is $\text{C}=\text{O}$.

18. The compound of claim 17 wherein the moiety X-Y is selected from the group consisting of: C1-C10 alkyl, alkyl, cycloalkyl, heteroalkyl, arylalkyl, aryl, heteroaryl and alkylaryl.

19. The compound of claim 18, wherein:




wherein R^b is connected directly to A and R^c is connected directly to W; and the moiety U^1 , U^2 , U^3 , U^4 , U^5 and U^6 form either a six membered carbon ring, or a five or six membered ring with one or more heteroatoms;

R^a = H, alkyl, alkoxy, hydroxy, alkylthio, halogen, nitro, cyano, carboxylic acid, ester, amide, amino, nitrile, or CF_3 ;

R^b is a bond, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, O, S, SO_2 , NH, O(alkyl), S(alkyl), SO_2 (alkyl) or N(alkyl); and





R^c is a bond, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, O, S, SO_2 , NH, O(alkyl), S(alkyl), SO_2 (alkyl), N(alkyl) or CH_2 -N(alkyl) with the CH_2 being linked to the aromatic ring.





20. The compound of claim 18 wherein the moiety X-Y is selected from the group consisting of the following structures:











21. A pharmaceutical composition comprising as an active ingredient a compound of claim 1.
22. The pharmaceutical composition of claim 21 for use in treating disorders associated with Hepatitis C virus.
23. The pharmaceutical composition of claim 21 additionally comprising a pharmaceutically acceptable carrier.
24. A method of treating disorders associated with the HCV protease, said method comprising administering to a patient in need of such treatment a pharmaceutical composition which composition comprises therapeutically effective amounts of a compound of claim 1.





25. The use of a compound of claim 1 for the manufacture of a medicament to treat disorders associated with the HCV protease.
26. A method of preparing a pharmaceutical composition for treating disorders associated with the HCV protease, said method comprising bringing into intimate contact a compound of claim 1 and a pharmaceutically acceptable carrier.
27. A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers and tautomers of said compound, and pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the group of compounds with structures listed below:





























28. A pharmaceutical composition for treating disorders associated with the HCV protease, said composition comprising therapeutically effective amount of one or more compounds in claim 27 and a pharmaceutically acceptable carrier.

29. The pharmaceutical composition of claim 28, additionally containing an antiviral agent.

30. The pharmaceutical composition of claim 28 or claim 29, still additionally containing an interferon.

31. The pharmaceutical composition of claim 30, wherein said antiviral agent is ribavirin and said interferon is α -interferon.

包含烷基和芳基丙氨酸P2部分的丙型肝炎病毒的大环NS
3-丝氨酸蛋白酶抑制剂

本发明公开了具有HCV蛋白酶抑制活性的新的大环化合物，以及制备这种化合物的方法。在另一个实施方案中，本发明公开了包含这种大环化合物的药物组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。